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ABSTRACT 
 
THE EVOLUTION OF PLATELET RESPONSES TO COLLAGEN UNDER 
CONDITIONS OF HEMODYNAMIC FLOW 
 
Author:  Alec A. Schmaier 
Supervisor:  Mark L. Kahn 
 
Collagen activates platelets through the immune-type GPVI receptor, but the mechanism 
by which this receptor has adapted to function in platelets under conditions of rapid blood 
flow is unclear.  Additionally, it is unknown if responses to collagen are conserved in 
nucleated thrombocytes found in non-mammalian vertebrates, which do not express 
GPVI.  Here we show that the GPVI proline-rich domain accelerates GPVI signaling 
kinetics and is required for maximal adhesion to collagen under flow.  The proline-rich 
domain accelerates signaling through binding and directly activating the Src-family 
kinase Lyn.  Chicken thrombocytes are potently activated by collagen but do not form 3-
dimensional aggregates under arterial flow conditions, a profound contrast to platelet 
function.  Despite selective expression of most platelet-specific genes, thrombocytes 
contain a significantly lower density of !2b"3 integrin on the cell surface.  These studies 
identify a novel molecular mechanism by which GPVI accelerates immune signaling 
kinetics and demonstrate partial conservation of hemostatic cell responses to collagen 
under flow. 
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Chapter 1—Introduction:  Platelet responses to collagen and the role of GPVI 
 
Summary 
Platelets are essential for normal hemostasis, but their activation also underlies the 
disease mechanisms of heart attack and stroke.  This introductory chapter focuses on the 
role of collagen in platelet-mediated thrombus formation following vessel injury and the 
role of GPVI as the primary activator of platelets in response to collagen. 
 
Overview of platelets and collagen in hemostasis and thrombosis 
Warm-blooded organisms, including mammals and birds, circulate blood at high 
pressures to perfuse organs at a level commensurate with tissue metabolism.  Since an 
adequate amount of blood perfusion is required to maintain tissue oxygenation and 
removal of CO2 and waste products, highly evolved mechanisms exist within each 
species to prevent excess blood loss.  Hemostasis, the cessation of bleeding, involves the 
coordination of both a cellular component made up of platelets and a plasma protein 
system consisting of coagulation factors present in circulating blood (Fig. 1-1)
1
.  In its 
extreme form, excess hemostasis leads to thrombosis, the occlusion of a blood vessel, 
which is physiologic in preventing catastrophic hemorrhage following traumatic vessel 
injury but is pathophysiologic during injury in diseased arteries, leading to acute 
myocardial infarction and stroke.   
Blood vessel injury exposes pro-thrombotic material, such as tissue factor and 
collagen, to circulating blood.  Tissue factor exposure leads to the generation of thrombin 
 2 
through coagulation cascade activation, and thrombin activates platelets and cleaves 
fibrinogen into fibrin to promote clot formation.  Collagen is the major protein 
component of the extracellular matrix (ECM) that lies beneath the endothelial cell layer 
lining the blood vessels.  Exposure of subendothelial collagen initiates two processes:  (1) 
rapid platelet activation and (2) factor XII autoactivation with factor XIa formation 
leading to thrombin formation
2
.  Both activities, along with thrombin generation, 
contribute to the formation of a platelet plug, resulting in further coagulant activity and 
the production of a fibrin-containing thrombus.  Determining how platelets adhere and 
are activated by exposure of ECM components is essential to understanding the 
pathogenesis of acute thrombotic cardiovascular disease. 
 
Platelets in human cardiovascular disease 
The primary physiologic function of platelets is to stop hemorrhage after tissue trauma 
and vessel injury and to initiate an inflammatory response to repair the injury.  The 
importance of platelets in hemostasis is evident by the increased risk of bleeding in 
patients who are thrombocytopenic, taking anti-platelet agents such as aspirin or 
clopidogrel, or lack critical platelet receptors such as in Glanzmann’s thrombasthenia or 
Bernard-Soulier syndrome.  However, platelets have a causal role in the pathologic 
thrombosis of cardiovascular disease.  Cardiovascular disease, both coronary and 
cerebrovascular, is the leading cause of death in the United States and worldwide and, as 
a chronic condition, is predominantly associated with atherosclerosis
3
.  Coronary 
atherosclerosis is unquestionably the leading cause of acute coronary syndromes, 
 3 
including unstable angina, acute myocardial infarction and sudden cardiac death
4
.  The 
primary event mediating athero-thrombosis is believed to be rupture of an unstable, non-
stenotic atherosclerotic plaque, which exposes pro-thrombotic material and leads to 
platelet-mediated occlusive thrombus formation
5,6
.  A major goal in the study of platelet 
biology is aimed at better understanding the mechanisms underlying acute thrombosis in 
the setting of atherosclerotic disease.  Anti-platelet agents that target major components 
of platelet function are first-line in treatment of cardiovascular disease.  However, the 
association of these drugs with bleeding complications underlies the importance for 
development of more refined platelet inhibitors that specifically target athero-thrombotic 
pathophysiology without interfering with physiologic hemostasis. 
 
Platelet and thrombocyte biology 
Platelets are uniquely suited to serve as hemostatic cells in mammalian physiology.  They 
are the smallest cell type found in circulating blood, averaging a diameter of 2.0 to 3.0 
µm and a thickness of 0.5 µm, and they lack a nucleus7.  Platelets are produced from 
megakaryocytes, large polyploid cells found primarily in the bone marrow, by protrusion 
of long, beaded cytoplasmic extensions called proplatelets into the bone marrow 
sinusoids where they can be released to enter the bloodstream
8
.  Once in the blood, 
platelets may circulate for a lifespan of 7-10 days before being destroyed by the 
reticuloendothelial system of the spleen.  Platelets are extremely numerous in the 
circulation—a normal platelet count is 150-450,000 per µL in humans and can be greater 
than 1 x 10
6
 per µL in mice—making them excellent surveyors of vascular integrity, 
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ready to respond immediately, in large numbers, at the site of vessel injury.  However, 
platelets are not found in all warm-blooded species with a high-pressure vascular system.  
Platelets are unique to mammals, whereas non-mammalian vertebrates contain 
thrombocytes—larger, nucleated cells, tenfold less numerous than platelets, that are 
believed to serve an analogous hemostatic function.  Much less is known about the 
biology of thrombocytes, their protein expression, or their function in vivo.  Chapter 3 
will compare the biology of mammalian platelets to that of avian thrombocytes to 
determine if responses to collagen in cellular hemostasis are conserved throughout 
evolution.   
 
Effects of blood rheology on platelet interaction with the vessel wall 
Blood rheology is an important component for platelet activation under arterial 
conditions.  Blood flow is considered to be laminar, meaning that layers of blood pass 
each other at different velocities, resulting in a flow gradient where the velocity is highest 
in the middle of the vessel and almost zero at the vessel wall
9
.  The flow velocity gradient 
is highest near the edge of vessel and very small near the middle of the vessel.  As a 
result of this velocity gradient, shear rate (!), the rate at which flow velocity changes 
(expressed as s
-1
), and shear stress ("), the tangential force per unit area exerted in the 
direction of flow (expressed as dynes/cm
2
), are greater at the vessel wall than in the 
middle of the vessel.  Areas of increased shear rate and shear stress, such as the edge of 
the vessel wall, have a positive effect on platelet adhesion
9,10
.   
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The shear rates are very low in large vessels but increase to 1500 s
-1
 in small 
arteries and can increase dramatically to 40,000 s
-1
 in stenosed arteries
11
.  This increased 
vessel shear rate in the setting of atherosclerosis is certainly an important factor 
contributing to pathologic activation and adhesion of platelets.  The presence of red blood 
cells, which normally occupy 38-48% of blood volume, also has a profound effect on 
platelet distribution within a vessel.  As shear rates increase, red blood cells are found 
toward the center of the vessel, and the smaller platelets are pushed toward the vessel 
edge, further facilitating platelet interaction with the vessel wall
12
.  Increased blood 
viscosity also exerts a positive effect on platelet deposition
13
.  The higher shear rate and 
shear stress of stenosed arteries and the role of blood viscosity are all contributing factors 
in the setting of arterio-thrombotic cardiovascular disease.  Chapters 2 and 3 will examine 
the adhesion and aggregation of platelets in response to collagen, using flow chambers 
that reproduce arterial flow conditions. 
 
Platelet activation 
Several aspects of platelet cell biology allow for an efficient response to vascular injury.  
Upon encountering subendothelial ECM components such as von Willebrand Factor 
(vWF) or collagen and being exposed to soluble activators such as thrombin, adenosine 
diphosphate (ADP), serotonin (5-hydroxytryptamine or 5-HT), or thromboxane (TXA2), 
platelets undergo a rapid and coordinated process of shape change associated with the 
transition from a quiescent to an activated state.  Platelet activation is associated with cell 
spreading, which allows platelets to flatten and cover a damaged surface through 
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lamellipodia formation.  Activation and recruitment of additional platelets is facilitated 
by filopodia extension.  These spreading processes involve dynamic reorganization of the 
actin cytoskeleton and expansion of platelet surface area through recruitment of extensive 
membrane infoldings called the open canalicular system.  The ability of platelets to 
rapidly change from a discoid shape to a flattened, spread shape is crucial to their 
functioning effectively as hemostatic cells.  In Chapter 3, the ability of avian 
thrombocytes to perform these spreading processes will be examined to determine if this 
element of cellular hemostasis is conserved through evolution.   
 
Platelet responses to collagen under arterial flow conditions 
Thrombus formation at the sites of arterial injury requires the coordinated process of 
platelet adhesion, activation, degranulation, and aggregation.  These events occur within 
seconds in the high-flow environment of the arterial system, and an individual platelet 
has only nano- to microseconds during which to interact with a site of vascular injury.  
Fibrous collagens, especially types I and III, constitute up to 40% of the proteins of the 
vessel wall, and these are the major ECM proteins that support robust platelet adhesion 
and activation
14
.  Along with thrombin generation, collagen exposure to the rolling 
platelet is a primary event in platelet-mediated thrombosis (Fig 1-1).  Platelets express 
two receptors, glycoprotein VI (GPVI) and the #2$1 integrin, which have significant roles 
in the interaction of platelets with collagen
15,16
.  Chapter 2 will discuss a unique element 
of GPVI signal transduction.  Chapter 3 will consider collagen-induced cellular 
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hemostasis in the chicken, which does not have platelets but instead has larger, nucleated 
thrombocytes that do not express GPVI. 
 
GPVI is a platelet receptor for collagen 
The role of GPVI as a platelet collagen receptor was initially based on the observation 
that patients deficient in this protein exhibit a bleeding tendency and defective platelet 
aggregation in response to collagen
15,17
.  GPVI is mapped to a gene cluster known as the 
leukocyte receptor complex (LRC, on chromosome 19 in humans) which includes killer-
inhibitory receptors (KIRs), leukocyte Ig-like receptors (LILRs), and the IgA receptor 
Fc#RI, among other Ig-domain containing receptors18,19.  As an LRC gene, GPVI is a 
member of the paired immunoglobulin (Ig) receptor superfamily but is expressed 
exclusively on platelets and megakaryocytes
20
.  The closest homolog of GPVI is Fc#RI, 
expressed on neutrophils, eosinophils, monocyte/macrophages, and interstitial dendritic 
cells, and both GPVI and Fc#RI require association with the adaptor protein FcR! via 
transmembrane arginines on the receptor for normal surface expression and signal 
transduction
18,21,22
.   
The absence of 11 consecutive amino acids in the sequence of GPVI, compared to 
that of Fc#RI, creates a shallow hydrophobic groove on the surface of the distal Ig 
domain that forms a putative collagen-binding site
23
.  GPVI is believed to exist as a dimer 
where two GPVI Ig domains form parallel collagen binding grooves
23,24
.  GPVI only 
recognizes fibrillar, not monomeric, collagen and binds to glycine-proline-
hydroxyproline (GPO) triplets that constitute about 10% of the primary sequence of 
 8 
collagens type I and III
25
. While the heterogeneity of collagen ligand makes it difficult to 
determine an absolute affinity, GPVI appears to be a relatively low-affinity collagen 
receptor, with the estimated Kd of GPVI and collagen being 57 µM
24,26
.  Additionally, 
GPVI is capable of binding and activating platelets in response to laminin, another 
subendothelial basement membrane protein that adopts a similar triple helical 
structure
26,27
.  This finding suggests that GPVI may function less as a highly specific 
collagen receptor and more as a sensor for the presence of ECM proteins.  Chapter 3 will 
consider whether chicken thrombocytes express collagen receptors capable of signal 
transduction and thrombocyte activation. 
The study of GPVI has been aided by the existence of high-affinity GPVI-specific 
ligands that readily induce GPVI clustering on the cell surface and subsequent platelet 
activation.  Synthetic collagen-related peptide (CRP) contains multiple runs of the GPO 
motif cross-linked to recapitulate the quaternary structure of collagen
28,29
, and the C-type 
lectin convulxin (CVX), isolated from the venom of the crotalus durissus terrificus, 
forms a hexamer that binds the proximal Ig domain of the receptor
30
.   
 
#2$1 integrin is a high-affinity collagen receptor  
The #2$1 integrin was the first collagen receptor to be identified on platelets and is 
expressed at copy numbers roughly equal to that of GPVI
31
.  The #2 subunit of this 
integrin contains an I (“inserted”) domain which binds collagen with relatively high 
affinity compared to GPVI (Kd = 35-90 nM) in a Mg
2+
-dependent manner.  #2$1 
recognizes the Gly-Phe-[hydroxy]Pro-Gly-Glu-Arg (GFOGER) motif, found in various 
 9 
collagen subtypes but constituting only about 0.02% of the primary collagen sequence
32
.  
A role for #2$1 in platelet activation has not been well established, although the integrin 
has the potential to transduce signal that could function in concert with GPVI signaling
33-
35
.  However, collagen-induced platelet activation responses such as aggregation, 
degranulation, and fibrinogen binding are almost completely normal in #2$1-deficient 
platelets
34,36
.  
Like the well-characterized #IIb$3 platelet integrin, one factor complicating the 
study of #2$1 is its strict dependence on “inside-out” signals to activate the integrin from 
a low- to high-affinity state where it is capable of binding ligand
37,38
. Platelet integrins, 
including #2$1, can be activated by G-protein coupled agonists such as thrombin and 
ADP.  However, the absolute dependence on GPVI signaling in ex vivo collagen assays 
suggests that when collagen is the sole activator, GPVI is required to stimulate #2$1 
before the integrin is able to bind ligand.  Regardless of how it is activated, #2$1 is 
required for firm adhesion to collagen under hemodynamic flow, serving as a high-
affinity collagen receptor that, once activated, arrests platelet translocation along the 
vessel wall
39-41
.  This dissertation will not focus on #2$1 directly, but it is important to 
consider its role in platelet adhesion to collagen under flow, which will be discussed in 
depth in Chapters 2 and 3.   
 
GPVI activates platelets through an immune-receptor signaling pathway 
Structure-function studies in platelets and cell lines have established that GPVI signal 
transduction mechanisms are analogous to immune receptor pathways seen in other 
 10 
hematopoietic cells.  Like other immune cell receptors, GPVI is believed to exist on the 
membrane within lipid rafts, and ligands that induce receptor clustering initiate GPVI 
signal transduction through colocalization of effector proteins
42,43
.  Upon receptor 
ligation, GPVI signal transduction is initiated as follows:  the GPVI-bound FcR! adaptor, 
which contains an immunoreceptor tyrosine-based activation motif (ITAM), is 
phosphorylated by membrane-bound Src-family kinases (SFKs), specifically Lyn and 
Fyn, leading to recruitment and activation of the tyrosine kinase Syk (Fig. 1-2).  Syk 
activation initiates assembly of a signaling complex via phosphorylation of the adaptor 
proteins linker for activated T-cells (LAT), Gads, and Src homology (SH)2 domain-
containing leukocyte phosphoprotein of 76 kD (Slp-76) (Fig. 1-2).  Assembly of this 
signaling complex leads to activation of phospholipase C (PLC!2).   PLC!2 cleavage of 
phosphatidylinositol 4,5-bisphosphate (PIP2) culminates in activation of protein kinase C 
(PKC) and generation of Ca
2+
 flux, a common endpoint for platelet activating signals 
(Fig. 1-2)
16,22,44-53
.  GPVI also employs signal transduction mechanisms that are unique 
compared to other FcR!-coupled immune receptors, and these observations will be 
described in Chapter 2.   
 
GPVI is required for collagen-induced platelet activation 
Genetic and pharmacologic studies have demonstrated that GPVI is both necessary and 
sufficient to activate platelets in response to collagen.  GPVI- or FcR!-deficient mouse 
platelets do not aggregate, degranulate, or activate integrins in response to collagen
36,54,55
.  
Deficiency of GPVI signaling effectors such as SFKs Lyn and Fyn, Syk, LAT, Slp-76, 
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and PLC!2 also abolishes collagen-induced platelet activation47,48,50,51,56,57.  In the 
absence of the other major platelet collagen receptor, #2$1, discussed later, GPVI is 
capable of inducing normal platelet activation in response to collagen
34,36
.  Additionally, 
expression of GPVI in cell line systems that express immune-type signaling effector 
molecules is sufficient for collagen-induced signal transduction
58,59
.   
Using various blood perfusion chamber approaches for both mouse and human 
platelets, GPVI-FcR! has been shown to be crucial for platelet adhesion to collagen under 
arterial shear conditions, an ex vivo response that most closely represents that function of 
platelets in vivo
36,40,60-62
.  Chapter 2 will address whether and how GPVI has adapted this 
immune receptor signaling pathway to accelerate platelet activation kinetics required for 
adhesion to collagen under flow. 
 
The role of GPVI in models of thrombosis and hemostasis 
Atherosclerosis involves pathological changes to the vessel wall, such as an increase in 
ECM deposition, especially that of collagen
63
.  Prothrombotic material exposed following 
plaque rupture induces strong platelet activation that is GPVI-dependent, thereby 
suggesting a role for GPVI in athero-thrombotic disease
64,65
.  Studies in the mouse aimed 
at establishing the importance of GPVI in mediating arterial thrombosis have produced 
varying results, likely due to the different types of arterial injuries produced by 
experimental models.  GPVI deficiency has little effect on thrombosis following laser 
injury to the cremasteric muscle arteriole, believed to be due to the fact that thrombosis in 
this model is thrombin-dependent and subendothelial collagen is not exposed
66-68
.  
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However, more extensive injury model systems can be employed, such as a ferric 
chloride (FeCl3)-induced injury to the cremasteric arterioles or mesenteric and carotid 
arteries, where reactive oxygen species destroy the endothelium and expose basement 
membrane collagen
69
.  In more substantial injury models, including FeCl3, GPVI-induced 
platelet activation is a requirement for thrombosis
67,70-72
.  Tail bleeding times of GPVI-
deficient mice are either normal or only slightly prolonged, however, suggesting that 
GPVI may not be essential for normal platelet function following minor trauma
54,55,73,74
.  
The role of GPVI in hemostasis and thrombosis in vivo will not be directly examined in 
this work.  However, the mechanism by which GPVI is able to rapidly activate platelets 
under hemodynamic flow conditions, a requirement for normal hemostasis and 
pathologic arterial thrombosis, which will be considered in Chapter 2.  Chapter 3 will 
address whether this fundamental mechanism of thrombus formation following collagen 
exposure is present in organisms that contain thrombocytes instead of platelets.    
 
The role of GPVI in human cardiovascular disease 
Increased expression of GPVI or #2$1 on platelets is associated with increased 
risk of athero-thrombotic disease and implicated as a negative prognostic biomarker in 
patients with cardiovascular disease
75-80
.  It has been difficult to determine a role for 
GPVI in hemostasis in humans since most cases of GPVI deficiency are seen in patients 
with anti-GPVI auto-antibody production associated with some degree of immune 
thrombocytopenia
81
.  Isolated deficiency of GPVI by compound heterozygosity, although 
extremely rare, is associated with only a mild bleeding diathesis
82,83
.  Together, the 
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finding that GPVI deficiency confers a protection from thrombosis, while not producing a 
bleeding phenotype, has generated interest in pharmacologic targeting of GPVI for 
therapeutic potential.  GPVI inhibition may help prevent the formation of pathologic 
thrombi associated with the coronary and cerebral arteries
70,84
.  Continued investigation 
of GPVI and collagen-induced cellular hemostasis as a fundamental mechanism of 
arterio-thrombotic disease and as a potential therapeutic target in humans is warranted.  
 
A model for platelet responses to collagen under flow and the role of GPVI 
Extensive work has demonstrated that, on a collagen-coated surface under hemodynamic 
flow in the absence of thrombin activity, platelets will translocate, or “roll,” along 
collagen, activate, firmly adhere, and form 3-dimensional aggregates
85
.  This process is 
initiated by platelet receptor GPIba/IX/V contact with collagen-bound vWF that is 
linearized by high shear forces on the vessel wall
10,86
.  The platelet-vWF interaction 
results in platelet translocation along the vessel edge and allows GPVI to interact with 
collagen and transduce signals that activate the platelet (Fig. 1-3).  GPVI binds collagen 
with low affinity and is therefore unlikely to directly mediate firm adhesion to collagen.  
However, GPVI signaling through FcR!, Syk, Slp-76, and PLC!2 is crucial for activation 
of high-affinity integrins, such as #2$1, which mediate firm adhesion to collagen, and 
#2b$3, which binds fibrinogen in plasma to cross-link platelets for aggregate formation 
(Fig. 1-3).  The fact that some platelet adhesion is observed in the absence of GPVI 
suggests that integrins can be activated to some degree through alternative pathways, 
perhaps through GPIb/V/IX signaling or shear force-induced conformational change of 
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integrins
87,88
.  GPVI signaling also results in platelet degranulation, releasing ADP and 
TXA2 that activate platelet G-protein coupled receptors in an autocrine and paracrine 
fashion to augment platelet activation and promote aggregate growth (Fig. 1-3).  
Furthermore, platelet activation through GPVI and positive-feedback pathways results in 
flattening of the platelet shape, another requirement for efficient aggregate formation.   
In vivo, platelet responses to collagen operate in conjunction with thrombin 
generation by the coagulation cascade and contributions from endothelial cells, becoming 
an increasingly complex process (Fig 1-1).  Chapter 2 will address how GPVI signaling 
has been adapted to efficiently transition the platelet from the rolling phase to the firmly 
adherent phase.  Chapter 3 will consider whether this model of collagen-induced 
activation under hemodynamic flow holds true for avian species that have thrombocytes 
instead of platelets.   
 
Conclusions and outstanding questions 
Platelet-mediated thrombus formation following atherosclerotic plaque rupture is the 
leading cause of cardiovascular death.  Studies aimed at understanding this 
pathophysiology should focus on platelet activation and aggregation under conditions of 
hemodynamic flow.  Collagen is a primary activator of platelets and the Ig-domain 
superfamily receptor GPVI is a platelet-specific receptor responsible for activation in 
response to collagen and platelet-mediated thrombosis.  While much progress has been 
made in describing the function of GPVI, many questions remain.  Those that will be 
addressed in this dissertation include: 
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How does GPVI, an immune-type receptor, function effectively to activate platelets under 
hemodynamic flow conditions? 
GPVI signal transduction utilizes a signal transduction pathway analogous to that of 
immune receptors found on T-cells and B-cells.  Receptor ligation induces clustering that 
results in phosphorylation of ITAM-containing adaptor molecules—FcR! in the case of 
GPVI—initiating a Syk, Slp-76, and PLC!2-dependent signaling cascade.  A major 
difference between immune cells and platelets is that signaling in immune cells is 
designed to take place over the course of hours, through immune synapse formation and 
results in gene transcriptional regulation.  GPVI must activate the platelet extremely 
rapidly to coordinate collagen-induced activation under conditions of hemodynamic flow.  
Whether and how GPVI has adapted this immune receptor signaling pathway to better 
suit the unique context of platelet physiology will be examined in Chapter 2.   
 
Is collagen-induced platelet activation a conserved element of cellular hemostasis? 
The ability of platelets to be activated by collagen is a fundamental aspect of platelet 
biology, and collagen-induced activation is mediated through GPVI.  Unlike other 
platelet-specific receptors that are extremely well conserved, GPVI is unique to non-egg-
laying mammals.  As an abundant and universal component of the subendothelial ECM in 
all species, collagen is well suited to serve as a hemostatic activator, yet the presence of 
GPVI appears to be a more recent product of evolution.  In the nucleated thrombocyte, a 
potential evolutionary precursor to the platelet, the ability to respond to collagen has not 
been thoroughly examined and will be discussed in Chapter 3. 
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Is occlusive thrombus formation universal to cellular hemostasis? 
Upon contact with collagen under hemodynamic flow, platelets form thrombi, and this 
process can lead to vessel occlusion.  The ability of platelets to mediate this response may 
be advantageous to mammals as a response to traumatic injury, in order to prevent 
catastrophic hemorrhage.  Unfortunately, this platelet response contributes to pathologic 
thrombosis in humans and is a major contributor to morbidity and mortality from 
cardiovascular disease.  Nucleated thrombocytes in avian species, which are larger and 
less numerous than platelets in mammalian species, may respond differently under 
hemodynamic flow conditions.  The ability of thrombocytes to form 3-dimensional 
aggregates under arterial flow conditions is unknown and will be examined in Chapter 3.  
Determining whether avian thrombocytes are capable of this function will be informative 
in understanding whether occlusive thrombus formation in response to vessel injury is a 
conserved element of hemostasis in other warm-blooded organisms with a high-pressure 
vascular system.  Studying this phenomenon in avian species will provide insight into the 
pathological mechanisms of mammalian platelet thrombosis that lead to human disease. 
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Figure 1-1.  A model for coagulation system and platelet activation following 
vascular injury in flowing blood.  
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Figure 1-1.  A model for coagulation system and platelet activation following 
vascular injury in flowing blood.   Flowing blood generates shear forces that promote 
platelet translocation along exposed collagen through GPIb/V/IX (GPIb) interaction with 
Von Willebrand Factor (vWF).  Collagen stimulates platelet activation through the GPVI 
receptor (GPVI).  Endothelial injury results in exposure of tissue factor (TF), which 
activates coagulation factor VII (VII to VIIa-TF) and leads to factor IX activation.  
Independently, exposed collagen supports factor XII (XII) autoactivation to enzymatic 
factor XIIa (XIIa).  XIIa initiates thrombin generation through a series of proteolytic 
reactions involving activation of factor XI (XI to XIa), which activates factor IX (IX to 
IXa).  Factor IXa and activated factor VIII (VIIIa) activate factor X (X to Xa), which 
along with activated factor V (Va) activates pro-thrombin (II) to thrombin.  Thrombin 
then stimulates platelets by activating its receptors, protease activated receptor 1 (PAR1) 
and 4 (PAR4).  PAR activation and GPVI signaling jointly contribute to platelet 
activation, which results in activation of integrins (#2$1) to mediate firm adhesion to 
collagen and exposure of procoagulant phophatidylserine (PS) on the platelet surface that 
promotes coagulation factor assembly.  These events converge to create a platelet 
thrombus, which amplifies into a fibrin clot and leads to arterial vessel occlusion. 
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Figure 1-2.  GPVI signal transduction.   
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Figure 1-2.  GPVI signal transduction.  Collagen binding GPVI induces receptor 
clustering that allows SFKs Lyn and Fyn to phosphorylate tyrosine residues located on 
the ITAM domain of the GPVI-bound FcR! chain.  FcR! phosphorylation results in 
recruitment of Syk kinase via its tandem SH2 domains.  Syk phosphorylates LAT and 
Slp-76 to assemble a signaling complex that includes the adaptor Gads bound to Slp-76.  
Assembly of this complex facilitates activation of PLC!2, which binds LAT via its SH2 
domain.  Throughout this process, SFKs are active in phosphorylating signaling complex 
components.  PLC!2 cleaves phosphatidylinositol 4,5-bisphosphate (PIP2) to generate 
inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG), which mobilize Ca
2+
 and 
activate PKC, respectively. 
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Figure 1-3.  The role of GPVI in platelet responses to collagen under flow.   
 
 
 
Figure 1-3.  The role of GPVI in platelet responses to collagen under flow.   
A model for platelet responses to collagen during hemodynamic flow in the absence of 
thrombin.  Platelet rolling along the vessel edge is mediated by platelet GPIb/V/IX 
interaction with collagen-bound vWF.  Platelet rolling allows for GPVI to interact with 
collagen and transduce signals that activate the platelet.  “?” refers to additional activators 
that can stimulate platelets in the absence of GPVI.  Platelet activation induces three 
essential processes:  (1) shape change, which flattens the platelet profile, allowing for 
more efficient contact with the collagen surface; (2) degranulation, which releases soluble 
activators ADP and TXA2 that increase platelet activation; and (3) activation of high-
affinity integrins #2$1 and #2b$3, which mediate firm adhesion to collagen and platelet 
aggregation via fibrinogen binding, respectively. 
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Chapter 2—Molecular priming of Lyn by GPVI enables an immune receptor to 
adopt a hemostatic role 
 
The data in Chapter 2 have been published in Proceedings of the National Academy of 
Sciences of the United States of America
152
. 
 
Summary 
Circulating platelets use the immune receptor homolog glycoprotein VI (GPVI) to 
respond to collagen exposed at sites of vessel injury.  In contrast to immune cell 
responses, platelet activation must take place within seconds to successfully form thrombi 
in flowing blood.  In this chapter, we show that the GPVI receptor utilizes a unique 
intracellular proline-rich domain (PRD) to accelerate platelet activation, a requirement 
for efficient platelet adhesion to collagen under flow.  The GPVI PRD specifically binds 
the Src-family kinase Lyn and directly activates it, presumably through SH3 
displacement.  In resting platelets, Lyn is constitutively bound to GPVI in an activated 
state, and platelets lacking Lyn exhibit defective collagen adhesion like that of platelets 
with GPVI receptors lacking the PRD.  These findings define a molecular priming 
mechanism that enables an immune-type receptor to adopt a hemostatic function.  These 
studies also demonstrate that active kinases can constitutively associate with immune-
type receptors without initiating signal transduction before receptor ligation.  
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Introduction 
Platelets circulate in a quiescent state but are rapidly activated at sites of vessel injury, a 
response essential for hemostasis in a high-pressure vascular system.  Platelet activation 
requires the generation of rapid and coordinated intracellular signals that culminate in 
cell-matrix and cell-cell adhesion and thrombus formation within seconds
10,85
.  Collagen, 
the most abundant and thrombogenic subendothelial matrix protein exposed by vessel 
injury, provides both a primary activating stimulus and an adhesive surface for the 
initiation of platelet thrombi in the arterial system. Molecular and genetic studies have 
established that collagen-induced platelet activation is triggered by the platelet-specific 
surface receptor glycoprotein (GP)VI.  GPVI is a low affinity collagen receptor and is not 
capable of mediating direct adhesion to collagen under flow, but is required to signal in 
response to collagen in order to mediate activation of the high-affinity integrin #2$1, 
which mediates firm adhesion to collagen.  The molecular mechanisms by which 
circulating platelets respond to collagen are of intense interest because of collagen’s 
primary role in arterial thrombosis.   
GPVI is an immunoglobulin (Ig)-like domain-containing receptor that is 
structurally and functionally homologous to immune receptors but is expressed 
exclusively on platelets and megakaryocytes
18,20
.  Extensive pharmacologic and genetic 
studies have demonstrated that GPVI signaling in response to collagen is highly 
analogous to that of the related multi-subunit T-cell receptor and the IgE and IgA 
receptors
46
.  GPVI ligands such as collagen or the snake venom toxin convulxin induce 
receptor clustering that facilitates the phosphorylation of the tandem tyrosines found in 
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the immunotyrosine activating motif (ITAM) of the non-covalently associated FcR! 
chain adaptor by Src-family tyrosine kinases (SFKs), specifically Lyn and Fyn.  ITAM 
phosphorylation stimulates the recruitment and activation of the intracellular tyrosine 
kinase Syk and assembly of an immune signaling complex (see Chapter 1).  This 
pathway, like the established G protein-coupled signaling pathways that mediate platelet 
activation by thrombin and ADP, results in the elevation of intracellular calcium levels 
and platelet activation responses, including granule release and integrin conformational 
changes.  In contrast to immune receptors that form stable immune synapses and transmit 
signals which generate cellular responses over several hours, platelet activation by GPVI 
takes place within seconds, allowing circulating platelets to firmly adhere to exposed 
collagen
36,89
.  Whether and how platelets have adapted the immune receptor homologue 
GPVI to meet the accelerated temporal requirements inherent in hemostasis is unknown.  
The signaling machinery of GPVI and other immune-type receptors is encoded by 
their short transmembrane and intracellular domains.  GPVI, like homologous immune 
receptors, contains a conserved transmembrane arginine that is required for its association 
with the FcR! chain, the essential signal transducing component of the receptor 
complex
21,90-92,93
.  However, a feature of GPVI that is unique among FcR!-coupled 
receptors is a conserved intracellular class I (R/K)xxPxxP proline-rich domain (PRD) of 
the amino acid sequence K/RPLPPLP that constitutes a core binding motif for SH3 
domains such as those found on SFKs
94
 (Fig. 2-1A).  Biochemical studies in cell lines 
have demonstrated that the GPVI PRD mediates binding to the SFKs Lyn and Fyn
95,96
.   
These studies have demonstrated variable degrees of reduced signaling by GPVI 
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receptors lacking this motif
59,95
.  Suzuki-Inoue et al. demonstrated reduced 
phosphorylation of the FcR! chain following stimulation of GPVI lacking the PRD in 
COS-7 cells transfected with GPVI constructs and FcR! chain95.  They also demonstrated 
an ablation of calcium mobilization in Jurkat T cells transfected with PRD-deleted GPVI, 
which associates with the ITAM-containing %-chains in this cell95.  Jurkat T cells do not 
express Lyn, however.  In contrast, Bori-Sanz et al. demonstrated a kinetic delay and 
reduced signaling strength of a GPVI truncation mutant that removed the PRD and distal 
C-terminal residues in rat basophilic leukemia (RBL)-2H3 cells that endogenously 
express FcR! chain and Lyn59.  The ability of cell line systems to accurately reproduce 
platelet biology is severely limited and cannot be used for studies under hemodynamic 
conditions.  The role of the GPVI PRD in platelets and hemostasis has not been defined.   
To study the function of the GPVI PRD, we generated mice with platelets that 
expressed wild-type GPVI or GPVI lacking the PRD.  Our studies reveal that the PRD 
does not alter the strength of sustained GPVI signaling but instead accelerates platelet 
activation kinetics, a feature required for the efficient adhesion of platelets to collagen 
under flow conditions.  Molecular studies to explain the basis for signal acceleration by 
the GPVI PRD reveal that this domain specifically binds the SH3 domain of Lyn.  We 
find that GPVI PRD binding directly activates Lyn and that GPVI-bound Lyn in resting 
platelets is in an active state prior to receptor ligation.  These studies provide insight into 
the molecular mechanism by which platelets have adapted the immune receptor signaling 
pathway to function under the temporal constraints of the hemostatic system. 
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Results 
GPVI receptors lacking the intracellular PRD are expressed on mouse platelets 
through retroviral transduction of hematopoietic progenitors. 
The proximity of the genes encoding GPVI and the homologous human Fc#RI and 
paralogous murine PIRa in the genome and their coupling to the FcR! transmembrane 
adaptor support a common evolutionary origin for these Ig-like domain-containing 
receptors
19
.  However, a feature of GPVI that is unique among these FcR!-coupled 
receptors is a conserved intracellular class I (R/K)xxPxxP PRD of the amino acid 
sequence K/RPLPPLP.  This region is a binding motif for SH3 domains such as those of 
Lyn and Fyn, which phosphorylate the FcR! ITAM (Fig. 2-1A)47,95,97,98.  The fact that 
this proline-rich sequence is restricted to the GPVI receptor suggests that it confers a 
platelet-specific signaling function. 
To examine the role of the GPVI PRD in platelet signaling, we used retroviral 
vectors to express wild-type human GPVI (WT GPVI) and a mutant lacking the PRD (PD 
GPVI) in GPVI-deficient hematopoietic progenitors that were subsequently transferred to 
irradiated host mice. The sequence of the cytoplasmic tail of human PD GPVI lacked 7 
amino acid residues unique to the PRD and was identical to that shown by Suzuki-Inoue 
et al. to no longer bind SFK SH3 domains (Fig. 2-1B)
95
.  Fetal liver cells from GPVI-
deficient embryos were infected with retrovirus driving the expression of GFP only, or 
GFP with either WT GPVI or PD GPVI, and these cells were used to reconstitute lethally 
irradiated wild-type host animals as previously described
99
.  In chimeric animals 
reconstituted with vectors that encoded WT or PD GPVI, GFP+ platelets co-expressed 
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surface GPVI (Fig. 2-1C).  As expected, these chimeric animals also contained a 
population of GFP-/GPVI- platelets derived from GPVI-deficient donor cells that were 
not successfully transduced with retrovirus (Fig. 2-1C).  The level of surface GPVI 
expression was constant and did not vary with the level of GFP expression (Fig. 2-1C), 
most likely because surface expression of GPVI receptors requires, and is limited by, the 
expression of endogenous FcR! co-receptors100.  The levels of GPVI expression were 
similar for WT GPVI and PD GPVI, indicating that both receptors are stably expressed 
on the platelet surface, and these levels were comparable to those found on human 
platelets (Fig. 2-1C and D).    
 
Loss of the GPVI PRD does not alter sustained GPVI signaling in platelets. 
Previous studies of GPVI signaling using cell lines have reported that GPVI receptors 
lacking the PRD signal more weakly than wild-type receptors, with virtually no signaling 
detected in the Jurkat T cell line and reduced signaling detected in the rat basophilic 
leukemia (RBL)-2H3 mast cell line
59,92,95
.  To test the role of the GPVI PRD in platelets, 
we exposed platelets from reconstituted animals to varying concentrations of the GPVI 
agonist convulxin for 10 min and measured platelet activation by the surface expression 
of P-selectin that occurs following intracellular granule release.  No significant difference 
in platelet activation by convulxin was detected between platelets expressing WT GPVI 
and PD GPVI receptors under these conditions (Fig. 2-2A and B).  The ability of PD 
GPVI platelets to spread and form lamellipodia on type-I collagen was not altered 
compared to that of WT GPVI platelets, whereas vector control, GPVI-deficient platelets 
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did not adhere well to collagen and did not spread on collagen (Fig. 2-2C and D).  
Together, these results indicate that the GPVI PRD is not required for sustained signaling 
in response to convulxin or collagen. 
 
The GPVI PRD is required for rapid platelet activation by GPVI. 
The GPVI PRD has been shown to bind the SFKs Lyn and Fyn, a finding which 
suggested that this domain might accelerate the initiation of GPVI signaling by 
facilitating the recruitment of Lyn and Fyn to the FcR! chain95,96.  To test the importance 
of the PRD in accelerating GPVI-mediated platelet activation, platelets were stimulated 
with convulxin, and the degree of platelet activation at varying time points was analyzed.  
Platelet activation was determined by the binding of the integrin #2b$3 ligand fibrinogen 
or by the activation state-specific anti-#2b antibody JON-A.  Consistent with the findings 
illustrated in Figure 2-2B, at 45 s the degree of activation was identical for WT GPVI and 
PD GPVI platelets (Fig 2-3A and B).  At time points of up to 30 s following convulxin 
stimulation, however, platelet activation was significantly impaired in platelets 
expressing PD GPVI receptors compared with those expressing WT GPVI receptors (Fig. 
2-3A and B).  A delay in activation of PD GPVI platelets was also observed in response 
to stimulation with collagen-related peptide (CRP), a synthetic collagen peptide specific 
for GPVI that activates platelets more slowly than convulxin
28
, whereas sustained 
signaling at timepoints of 90 and 180 sec was identical (Fig. 2-3C).   
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P-selectin expression is an appropriate readout for measuring sustained GPVI-
induced activation, whereas fibrinogen binding is preferable for measuring GPVI 
signaling kinetics. 
We have used P-selectin expression to compare platelet responses at 10 min, but we used 
fibrinogen binding for kinetic analysis of platelet activation at shorter time intervals.  The 
rationale for this approach is that P-selectin expression is slow compared to integrin 
activation/fibrinogen binding and does not provide as sensitive and accurate a means of 
kinetic analysis.  There is not a statistically significant increase in P-selectin expression 
before 45 sec following convulxin stimulation (Fig. 2-4A).  In contrast, fibrinogen 
binding is detectable much earlier, i.e. by 10 sec, and there is a statistically significant 
change between all early time points measured (Fig. 2-4B).  Conversely, we have found 
that the degree of fibrinogen binding can vary following a long stimulation, perhaps due 
to late signaling that downregulates integrin affinity, while P-selectin expression reaches 
a stable dose-dependent plateau and is therefore a good readout of total platelet 
activation.   
 
Loss of the PRD delays proximal GPVI signal transduction in RBL-2H3 cells. 
The first step in signal transduction by the GPVI receptor is the phosphorylation of FcR! 
intracellular tyrosines by SFKs, an event required for the binding and activation of the 
downstream kinase Syk
46
.  Retroviral complementation of GPVI-deficient bone marrow 
yields a limited number of animals that are chimeric, and these reconstituted mice often 
have a low percentage of platelets that express GPVI receptors.  Therefore, we could not 
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biochemically test the mechanism of delayed PD GPVI signaling in platelets.  To 
biochemically characterize PD GPVI signaling kinetics, we used lentiviral vectors to 
stably express equivalent levels of WT GPVI and PD GPVI receptors in RBL-2H3 cells 
(Fig. 2-5A).  The RBL-2H3 mast cell line expresses endogenous FcR! chain and has been 
used by our lab and others to study GPVI signaling
59,92
.  Following stimulation with 
convulxin, RBL-2H3 cells expressing PD GPVI exhibited delayed phosphorylation of 
Syk, the kinase activated following FcR! ITAM phosphorylation, relative to that of WT 
GPVI-expressing cells (Fig. 2-5B).  However, total Syk phosphorylation at later time 
points was unchanged (Fig. 2-5B).  We attempted to measure the kinetics of FcR! chain 
phosphorylation, the primary event in GPVI signaling, in WT- and PD-GPVI-expressing 
RBL cells.  However we were unable to detect FcR! phosphorylation in this cell line 
system for technical reasons (data not shown).  Lastly, elevation of intracellular Ca2+ 
was slower following GPVI stimulation in PD-GPVI expressing cells compared to that in 
WT GPVI-expressing cells (Fig. 2-5C).  
 
The GPVI PRD is required for efficient platelet adhesion to collagen under flow.  
The physiologic role of the GPVI receptor is to activate circulating platelets that come 
into contact with collagen at sites of vessel injury in vivo.  Under experimental conditions 
of blood flow over a collagen-coated surface, GPVI signaling is essential for the 
transition from platelet rolling, mediated by the GPIb-von Willebrand Factor interaction, 
to firm adhesion, mediated by activated #2$1 integrin-collagen interaction (see Chapter 
1)
10,36,40,85
.  To determine the role of the GPVI PRD during GPVI-collagen signaling 
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under flow conditions, whole blood from reconstituted animals was flowed over a type-I 
collagen patch in a microfluidic chamber, and platelet rolling and adhesion were analyzed 
in real time.  Since each reconstituted mouse is a chimeric animal containing different 
percentages of GFP+/GPVI+ and GFP-/GPVI- platelets, the overall amount of platelet 
accumulation was not representative of how efficiently individual platelets activated 
transition from the rolling phase to firm adhesion.  Therefore, the amount of platelet 
accumulation could not be used to compare the function of WT GPVI and PD GPVI 
receptors.   
To overcome this limitation and analyze platelet adhesion in a cell-autonomous 
fashion, each flow experiment was analyzed frame-by-frame, and all rolling platelets 
were tracked to determine if and when they firmly adhered to the collagen surface (Fig. 
2-6).  An “adhesive efficiency” for each experiment was determined by a / (a + r), where 
a equals the number of platelets that permanently adhered and r equals the number of 
platelets that rolled along collagen but did not adhere.  The difference in adhesive 
efficiency between WT GPVI-expressing platelets and vector control, GPVI-deficient 
platelets was profound and consistent with previous observations that GPVI-deficient 
platelets are unable to adhere to collagen under flow conditions (Fig. 2-7A)
36,40,70
.  A 
majority of WT GPVI platelets that rolled along the collagen surface successfully 
adhered, with an adhesive efficiency of 0.65 ± 0.11, whereas only a small number of 
vector control GPVI-deficient platelets were able to transition from rolling to firm 
adhesion, with an efficiency of 0.09 ± 0.04 (Fig. 2-7A).  PD GPVI-expressing platelets 
exhibited a markedly reduced adhesive efficiency of 0.31 ± 0.15, demonstrating that, 
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compared to WT GPVI, approximately half as many PD GPVI platelets were able to 
transition from the rolling phase to the firmly adherent phase (Fig. 2-7A).   
A second measure of how efficiently platelets adhere to collagen is the time 
required for each adherent platelet to transition from a rolling state to one of firm 
adhesion, i.e. the time each adherent platelet spends in the rolling phase.  Of the firmly 
adherent platelets, WT GPVI platelets spent a shorter time in the rolling phase compared 
to PD GPVI platelets (mean rolling time 711 ± 525 ms for WT GPVI versus 972 ± 674 
ms for PD GPVI; P < 0.0005) (Fig. 2-7B and C), a finding consistent with the slower 
kinetics of PD GPVI signaling which results in a longer time to activate platelet integrins 
and mediate firm adhesion to collagen.  These observations demonstrate that the GPVI 
PRD is required for efficient platelet adhesion to collagen under flow, the ex vivo 
response that most closely models the physiologic role of GPVI signaling in platelets in 
vivo.   
 
The GPVI PRD preferentially binds the SH3 domains of Lyn and Hck. 
To identify all the SH3 domain-containing proteins that might bind the GPVI PRD, we 
expressed WT GPVI and PD GPVI cytoplasmic tails as recombinant glutathione S-
transferase (GST)-fusion proteins in E. coli (Fig. 2-8A).  Incubation of these proteins 
with platelet lysate followed by GST pulldowns demonstrated the ability of the GPVI 
intracellular tail to bind Lyn and Fyn in a PRD-dependent manner (Fig. 2-8B).  Next, we 
used these recombinant proteins to screen a human SH3 proteome phage-display library 
in order to identify the preferred SH3 domain binding partners for a number of proteins 
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containing PRDs
101
.  The WT GPVI fusion protein served as an excellent SH3 domain 
target in this assay, binding approximately 1000-fold more SH3 domain-expressing 
phage than did the PD GPVI fusion protein or GST alone (Fig. 2-8C). The identity of the 
SH3 domains bound by GST-WT GPVI proteins was determined by sequencing the 
inserts of the selected phage clones after a single round of affinity selection.  Of 48 SH3 
domains bound by GST-WT GPVI proteins, 40 encoded the SH3 domains of SFKs 
(Table 2-I).  Of 48 clones sequenced in 3 independent experiments, 40 encoded the SH3 
domains of SFKs (Table 2-I).  Remarkably, 35/40 encoded the SH3 domain of either Lyn 
(16/40) or Hck (19/40) (Table 2-I).  These results suggest that the SH3 domains of the 
SFKs Lyn and Hck are specific binding partners of the GPVI PRD. 
To test the results of the SH3 domain phage display screen, we determined which 
of the putative partner proteins could be co-immunoprecipitated with endogenous GPVI 
receptors in human platelets.  Lyn co-immunoprecipitated with GPVI both under resting 
conditions and following receptor stimulation with convulxin (Fig. 2-8D).  In contrast, 
Fyn was observed to associate with GPVI receptors following receptor stimulation but to 
have little or no association with GPVI in the resting platelet (Fig. 2-8D).  The Fyn SH3 
domain was identified in the phage display screen, although as a rare binding partner 
compared to Lyn or Hck (Table 2-I).  As previously reported, Src did not co-
immunoprecipitate with GPVI (Fig. 2-8D).  Burton’s tyrosine kinase (Btk), whose SH3 
domain was also identified by phage display as a less frequent GPVI tail binding protein, 
did not associate with GPVI in platelets (Fig. 2-8D).  Consistent with previous studies
96
, 
we could not detect Hck expression in platelets (data not shown), suggesting that Hck is 
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not a physiologically relevant GPVI binding partner.  These findings identify Lyn as a 
constitutive GPVI PRD binding partner in platelets. 
 
GPVI PRD binding directly activates the Lyn and Hck kinases.  
Constitutive recruitment of Lyn to GPVI via an SH3-domain/PRD interaction could 
accelerate GPVI signaling merely by placing the kinase in close proximity to its 
substrate, the FcR! ITAM.  Alternatively, since SFKs can be activated via SH3-domain 
displacement
102
, GPVI PRD-Lyn SH3 domain binding could directly regulate the kinase 
activity of Lyn.  Hck and Lyn are efficiently activated through SH3 binding by the HIV-1 
protein, Nef
102,103
, and Hck and Lyn have been identified as the preferred binding 
partners for the Nef SH3 domain using the same SH3 phage display screen as that 
described above
101
.  We therefore reasoned that the GPVI PRD might activate Hck and 
Lyn through a mechanism similar to that of Nef.   
To determine if the GPVI PRD can directly activate Hck and Lyn, we used an in 
vitro kinase assay that has previously demonstrated direct Nef activation of these kinases 
103
. Recombinant Hck, Lyn, and c-Src were expressed in insect cells with a C-terminal 
modification that promotes autophosphorylation and confers an inactive kinase state
103
.  
Purified kinase activity was then assayed in vitro with a peptide substrate, either alone or 
in the presence of increasing concentrations of purified recombinant GST-WT GPVI, 
GST-PD GPVI, or Nef protein.  WT GPVI fusion protein activated Hck to a level 
comparable to that of Nef at similar molar ratios (Fig. 2-9A).  WT GPVI also induced 
strong activation of Lyn, even at low GPVI:Lyn molar ratios, to a significantly greater 
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extent than did Nef under the same conditions (Fig. 2-9B).  PD GPVI fusion proteins 
were unable to activate Hck or Lyn even at high molar excess, demonstrating the 
requirement for the GPVI PRD to mediate kinase activation (Fig. 2-9A and B).  
Consistent with the binding studies described above and with previous findings
103
, neither 
WT GPVI nor Nef were capable of inducing c-Src activation in vitro (Fig. 2-9C).  These 
observations demonstrate that GPVI functions as a direct activator of Hck and Lyn kinase 
activity, presumably via displacement of the intramolecular negative regulatory 
SH3/linker interaction within these kinases by the GPVI PRD. 
 
GPVI-bound Lyn is held in the active state in resting platelets. 
To determine if GPVI-bound Lyn is found in an activated state in vivo, we 
immunoprecipitated GPVI from human platelets under resting and stimulated conditions 
and used phospho-specific antibodies to assess the kinase activation state.  The SFK that 
co-immunoprecipitated with GPVI under both resting and stimulated conditions was 
phosphorylated at the activation loop, indicating that it was in the active state (Fig. 2-10).  
More strikingly, none of the GPVI-bound Lyn was found to be phosphorylated on its 
negative regulatory tail, despite a large amount of cellular Lyn that was found in this 
inactive state (Fig. 2-10).  These findings indicate that GPVI-associated Lyn is 
exclusively in the active state even in resting platelets.  The activation-loop 
phosphotyrosine antibody used in these experiments recognizes all SFKs, but our studies 
identified Lyn as the only SFK that associates with GPVI in resting platelets (Fig 2-8D).  
In these assays the antibody reproducibly detected a doublet at 53 kD and 56 kD that is 
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characteristic of Lyn (Fig. 2-10).  To ensure that the detection of activated Lyn associated 
with GPVI in resting platelets was not due to low-level platelet activation during cell 
harvest, we assessed the phosphorylation state of the FcR! ITAM tyrosines.  Robust FcR! 
tyrosine phosphorylation was observed following 15 s of convulxin stimulation, but none 
was observed in resting platelets (Fig. 2-10), although small amounts of basal FcR! 
phosphorylation have been reported previously
104
.  These findings demonstrate that the 
Lyn associated with GPVI receptors in resting platelets is held in the active state but that 
the FcR! ITAM is not phosphorylated in the absence of receptor ligand. 
 
Lyn-deficient platelets exhibit the delayed GPVI receptor signaling and defective 
adhesion to collagen under flow characteristic of PD GPVI platelets. 
The studies described above suggest that the rapid early signal transduction conferred by 
the GPVI PRD is dependent upon association with active Lyn.  To test the dependence of 
this mechanism on Lyn, we examined GPVI signaling and collagen adhesion under flow 
in mouse platelets lacking Lyn or Fyn.  As observed for PD GPVI platelets (Fig. 2-2), the 
dose response of Lyn-deficient platelets stimulated with convulxin for 10 min was similar 
to that of wild-type platelets (Fig. 2-11A), although at the lowest dose of convulxin 
stimulation a gain of function was observed in Lyn-deficient platelets consistent with 
previous findings
47
.  However, when platelet activation responses were examined at short 
time points following GPVI receptor stimulation, a delay in the activation of Lyn-
deficient platelets similar to that of PD GPVI platelets was observed (Fig. 2-11B).  In 
contrast, Fyn-deficient platelets did not demonstrate a significant delay in GPVI-induced 
 37 
platelet activation at short time points (Fig. 2-11C).  Fyn-deficient platelets, however, 
exhibited a defect in activation following convulxin stimulation for 10 min, as previously 
reported (Fig. 2-11D)
47
.   Like PD GPVI platelets, Lyn-deficient, but not Fyn-deficient, 
platelets exhibited a significant defect in adhesion to collagen under flow (Fig. 2-12A and 
B).  These studies reveal that rapid GPVI signals require both the GPVI PRD and Lyn 
kinase.  Similar to loss of the GPVI PRD, loss of Lyn confers delayed GPVI receptor 
signaling and defective adhesion to collagen under flow.
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Discussion 
Immune-type receptors are expressed by non-immune cells where they have adopted new 
functions, but the molecular adaptations that have fostered such novel roles remain 
unknown.  In the present study we identify the binding and direct activation of Lyn by the 
PRD of the GPVI receptor as a molecular mechanism by which platelets accelerate 
immune receptor signaling to adapt it to hemostasis, a biological response that must take 
place within seconds.  Previous studies have demonstrated that the GPVI PRD binds 
SFKs and contributes to GPVI signaling in cell lines
95,96
, but the molecular consequences 
of GPVI PRD interaction with SFKs and the functional role of this interaction in platelet 
responses was unknown.  Our results demonstrate that the PRD is not essential for GPVI 
signaling, but instead primes the receptor for rapid platelet activation required for 
efficient adhesion to collagen in the setting of blood flow by binding and directly 
activating Lyn.  Additionally, these findings identify a novel molecular mechanism by 
which an immune receptor has become a hemostatic receptor, and they provide insight 
into the basic mechanisms of immune receptor signal transduction. 
The activation of circulating platelets by exposed vessel wall collagen must take 
place within seconds for effective hemostasis, and GPVI is essential in this process 
10,36,40,70,85
.  GPVI is an immune-type receptor that signals through a pathway 
characterized by sustained and progressive signaling responses that do not typically result 
in extremely rapid cellular responses
89,105
.  A large number of molecular and genetic 
studies have demonstrated that GPVI signaling in platelets is similar to that of related 
receptors in immune cells
16,22,44-50
.  While these studies have confirmed that GPVI is 
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functionally a bona fide member of the immune receptor family, they have not addressed 
the way in which this signaling pathway has been adapted in platelets to serve a 
hemostatic role.  Our findings suggest that the GPVI PRD is therefore a specialized 
region that accelerates immune-receptor signaling to function in a non-immune, 
hemostatic role. 
This study provides new biological insight into the molecular regulation of SFKs 
through identification of an unexpected mechanism by which the GPVI PRD accelerates 
immune receptor–induced cellular activation.  The GPVI PRD selectively binds the SH3 
domains of Lyn and Hck and directly activates these kinases in vitro.  The ability of the 
GPVI PRD to activate Lyn directly by binding to its SH3 domain provides a striking 
example of how this mechanism, first described in studies of the HIV-1 Nef protein, has 
an important role, not previously appreciated, in endogenous biological responses
106,107
.  
Studies of Hck activation by Nef support a model in which binding of Nef to the SH3 
domain of Hck displaces the SH3 domain from an intramolecular association with a 
polyproline II helix in the SFK linker that holds the kinase in an inactive state
108
.  
Although studies of Nef have demonstrated SH3 domain displacement to be a potent 
mechanism of SFK activation that likely contributes to HIV virulence
102,103
, the extent 
and purpose to which endogenous proteins activate SFKs by this mechanism is not clear.  
Our studies suggest that GPVI activation of Lyn occurs through a Nef-type SH3 
displacement mechanism, although structural studies comparing SFK activation by these 
two proline-rich polypeptides are needed to determine whether or not they are 
molecularly identical.  Interestingly, our in vitro studies demonstrate that, like Nef, the 
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GPVI PRD can activate forms of Lyn and Hck which are phosphorylated at their 
negative-regulatory C-terminal tail tyrosines, suggesting that these two regulatory 
mechanisms can function independently
109,110
.  However, our analysis of GPVI-
associated Lyn in platelets reveals that virtually none is C-terminally tyrosine 
phosphorylated, suggesting that GPVI binding to the Lyn SH3 domain may also 
positively regulate kinase activity by promoting dephosphorylation at this negative 
regulatory site.  Future studies addressing the molecular basis of Lyn activation by GPVI 
may reveal whether and how these two molecular mechanisms of SFK regulation are 
coordinated in vivo. 
While both Lyn and Fyn are required for optimal GPVI signaling
47
, our studies 
suggest Lyn, but not Fyn, drives the explosive GPVI signaling required for adhesion to 
collagen under flow.  The preference of the GPVI PRD for binding Lyn over Fyn and the 
observation that Lyn, but not Fyn, binds GPVI receptors in resting platelets support a 
division of labor in which PRD-bound Lyn drives initial GPVI-induced platelet activation 
and Fyn participates in more sustained GPVI signaling.  This model of SFK signaling 
downstream of GPVI is supported by biochemical studies demonstrating a delay in FcR!, 
Syk and PLC!2 phosphorylation following GPVI stimulation of Lyn-deficient 
platelets
111
.  Consistent with this model, PD GPVI receptors exhibit delayed Syk 
phosphorylation and calcium signaling in RBL-2H3 cells.   
A final question raised by these findings is whether GPVI-bound activated Lyn 
affects other Lyn substrates in the platelet.  There are roughly 1500 GPVI receptors 
expressed on the platelet surface
58
, a number that is likely to be considerably lower than 
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the total quantity of intracellular Lyn.  We therefore speculate that GPVI-induced 
activation of Lyn is unlikely to significantly affect the phosphorylation of other Lyn 
substrates because of both physical sequestration of the activated kinase and the relatively 
small effect on the activation state of total Lyn. 
Our studies also provide unexpected insight into ITAM activation, a primary step 
in all immune receptor signal transduction.  An apparent paradox raised by our findings is 
how the GPVI receptor can constitutively associate with activated Lyn kinase yet not 
phosphorylate the ITAM of its co-receptor FcR! and activate the resting platelet.  A 
recent study of ITAM phosphorylation by the T cell receptor has revealed that the CD3& 
ITAM is embedded in the lipid bi-layer of the cell membrane and sequestered from 
activating SFKs in unstimulated cells
112
.  Through a yet undefined mechanism, T cell 
receptor ligation and clustering result in release of the ITAM from the membrane, 
exposure to SFKs, and initiation of downstream receptor signaling
112
.  These findings 
suggest that a similar sequestration of the FcR! ITAM in the cell membrane may allow 
activated Lyn to be held by GPVI in the immediate proximity of the FcR! subunit 
without initiating signal transduction prior to receptor-ligand interaction (Fig. 2-13).  
Future studies of GPVI-FcR! signaling in platelets, e.g., mutation of the acidic membrane 
proximal residues in FcR! proposed to mediate lipid interaction and separation from the 
GPVI receptor tail
93,112
, may be informative regarding both the basis of signal 
acceleration by the GPVI PRD and ITAM signaling by immune receptors. 
It is intriguing to consider the appearance of the GPVI PRD in the context of 
platelet and immune receptor evolution.  Adaptive immunity and ITAM signaling 
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receptors emerged over 500 million years ago with jawed vertebrates
113
, while platelets 
appeared more recently in mammals, 300 million years ago
7
.  The GPVI receptor is 
encoded by a gene in the leukocyte receptor complex (LRC), a region of the mammalian 
genome that underwent rapid evolution between egg-laying mammals, such as the 
platypus, and placental and marsupial mammals
114,115
.  Consistent with its location within 
the re-organized mammalian LRC, homology-based searches reveal clear GPVI orthologs 
in the genome of placental and marsupial mammals but not in the platypus or avian 
genomes.  Thus the GPVI receptor appears to have evolved with other LRC immune 
receptors after platelets had already appeared in mammals (see Chapter 3).  Alignment of 
the predicted opossum and human GPVI receptor amino acid sequences reveals the 
presence of a highly conserved intracellular PRD that is present in all known GPVI 
receptors (Fig. 2-1A).  These observations suggest that acceleration of immune receptor 
signaling by the PRD may have been instrumental in the evolution of GPVI as a platelet 
collagen receptor. 
The identification of a molecular mechanism by which an immune-type receptor 
accelerates signal transduction to perform a hemostatic function in platelets may also 
direct new therapeutic strategies to treat cardiovascular disease.  Collagen activation of 
platelets is a primary event in the formation of arterial thrombi that cause heart attack and 
stroke.  Agents that target the PRD of GPVI may selectively block rapid platelet collagen 
responses without inhibiting overall hemostasis and non-hemostatic immune receptor 
signaling. 
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Materials and methods 
Animals 
GPVI-deficient and Lyn-deficient mice have been previously described
54,116
.  Wild type 
C57/BL6 mice were purchased from Charles River Laboratories (Wilmington, MA).  All 
of the mice used for study were maintained in the animal
 
facility of the University of
 
Pennsylvania in accordance with National Institute of Health guidelines and approved 
animal protocols. 
 
Antibodies and reagents 
Anti-human GPVI monoclonal antibodies HY101 and 6B12 were produced as previously 
described 
58
 and were conjugated with Alexa Fluor-647 using the Monoclonal Antibody 
Labeling Kit purchased from Molecular Probes (Eugene, OR).  Convulxin, AYPGKF 
peptide, and PE-conjugated anti-murine CD62P (P-selectin) antibody were purchased 
from previously described sources
117
.  Collagen-related peptide (CRP) was obtained from 
Dr. Richard Farndale (Cambridge, UK).  FITC-conjugated polyclonal anti-rabbit Ig was 
purchased from BD PharMingen (Eugene, OR).  JON/A, JAQ1, and Leo.H4 monoclonal 
antibodies were purchased from Emfret Analytics (Eibelstadt, Germany).  Type-I fibrillar 
collagen (1 mg/mL) derived from equine tendon was purchased from Chronolog 
(Havertown, PA).  Purified acid-soluble fibrillar collagen (PureCol™) derived from 
bovine hide (3 mg/mL) was purchased from Inamed (Freemont, CA).  Rat anti-mouse 
CD41 (integrin #2b) monoclonal antibody was purchased from BD Biosciences (San Jose, 
CA).  Alexa-Fluor 488 and 647 Monoclonal Antibody Labeling Kits, Alexa-Fluor 647-
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conjugated human fibrinogen, and Alexa-Fluor 594-conjugated phalloidin were 
purchased from Invitrogen (Carlsbad, CA).  Murine stem cell factor (MSCF), IL-3 and 
IL-6 were purchased from PeproTech (Rocky Hill, NJ).  Anti-GFP, anti-Lyn, anti-Fyn, 
anti-Syk, and anti-Btk rabbit polyclonal antibodies were obtained from Santa Cruz 
Biotechnology (Santa Cruz, CA).  Anti-FcR! chain rabbit polyclonal antibody was 
obtained from Abcam (Cambridge, MA).  Anti-phosphotyrosine mouse monoclonal 
antibody 4G10 was obtained from Millipore (Billerica, MA).  Anti-phospho Src family 
(Y416), anti-phospho Lyn (Y507), and anti-phospho Syk (Y525/526) rabbit polyclonal 
antibodies, and anti-Src rabbit monoclonal antibodies were obtained from Cell Signaling 
(Beverly, MA). 
 
Retrovirus production 
The cDNA of human GPVI was subcloned into the p-GEM-T Easy vector (Promega, 
Madison, WI), and site-directed mutagenesis to remove the PRD was performed using the 
Stratagene QuickChange site-directed mutagenesis kit (La Jolla, CA).  The 
oligonucleotide used for site-directed mutagenesis has been previously described
95
.  
Wild-type and PRD deleted GPVI were subcloned into XhoI/HpaI sites of the murine 
stem cell virus MigR1 vector with an IRES-GFP inserted prior to the polyadenylation 
signal, as described previously
99
.  Production and titering of retrovirus was performed as 
previously described
118
.   For RBL-2H3 cell infections, wild-type
 
GPVI and GPVI 
lacking the proline-rich domain were subcloned into XbaI/EcoRI sites the HFUW 
lentiviral vector (kind gift from Dr. Eric Brown from Department of Cancer Biology, 
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University of Pennsylvania School of Medicine). The lentiviral vectors were packaged 
using HEK 293T cells. 
 
Fetal liver reconstitution 
Reconstitution of lethally irradiated animals with stem cells derived from fetal liver was 
performed as previously described
99
.  Briefly, fetal liver cells from gp6
-/-
 embryos at E14-
E16 were harvested, and mononuclear cells were isolated using Lympholyte (Cedarlane 
Labs, Burlington, NC) gradient and cultured overnight in IMDM (Invitrogen) with 10% 
fetal bovine serum in the presence of 100 ng/mL MSCF, 20 ng/mL IL-3, and 10 ng/mL 
IL-6.  The cells were then spin-infected twice with gp6 retroviruses at a multiplicity of 
infection equal to 5 virions per cell.  A total of 1 x 10
6
 cells (250 !L per
 
mouse) were 
retro-orbitally injected into 8-10-week-old C57/BL6 donor mice that received a lethal 
dose of 900 cGy total body irradiation.  All platelet studies were performed at least 6 
weeks after transplantation. 
 
GPVI antibody staining 
For mice, a drop of blood was collected from the tail vein, whereas for humans a drop of 
blood was obtained from a finger-stick from a healthy donor into 100 µL of Tyrode’s 
buffer (137 mM NaCl, 1 mM MgCl2, 2.7 mM KCl, 3.3 mM NaH2PO4, 1 g/L BSA, 5.6 
mM glucose, 20 mM HEPES, pH 7.4) containing 15 U/mL heparin.  Diluted whole blood 
was incubated with Alexa-Fluor 647-conjugated HY101 anti human GPVI antibody at 2 
!l/mL for 30 min at room temperature, and samples were analyzed using flow cytometry. 
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Murine blood collection  
Mice were anesthetized with 16 !g/g body weight tribromoethanol, and 100 !L of whole 
blood was collected by retro-orbital bleeding with a heparinized capillary tube.  Platelet-
rich plasma (PRP) was obtained by diluting whole blood 1:2 in Tyrode’s buffer and 
performing centrifugation at 100 g for 4 min. 
 
Platelet spreading assay 
Lab-Tek II chamber slides (Thermo Fischer Scientific, Rochester, NY) were coated with 
type I fibrillar collagen at 30 µg/mL in 50 µM acetic acid for 16 h at 4 °C, washed 3 
times with PBS, and blocked with BSA 1 mg/mL in PBS for 30 min at room temperature.  
PRP was diluted to 2 x 10
7
 platelets per mL in modified Tyrode’s buffer (137 mM NaCl, 
20 mM HEPES, 2.7 mM KCL, 3.3 mM NaH2PO4, 5.6 mM glucose, 1 g/L BSA, pH 7.4) 
containing 1 mM MgCl2, and 5 x10
6
 platelets were incubated on the collagen-coated 
chambers for 45 min at 37°C.  Fixation, permeablizing, and staining were performed as 
previously reported
119
.  Following 3 washes in PBS, adherent platelets were fixed with 
3% paraformaldehyde in PBS for 40 min, washed 3 times in PBS, and permeablilized 
with 0.3% Triton X-100 in PBS with BSA 1 mg/mL for 2 h.  After 3 washes in PBS, 
platelets were incubated with anti-GFP rabbit polyclonal antibody (10 µL/mL) for 16 h at 
4°C, washed 3 times in PBS, and incubated with FITC-conjugated polyclonal anti-rabbit 
Ig (2 µL/mL) for 2 h at room temperature.  Filamentous actin was stained with Alexa-
Fluor 594-conjugated phalloidin (25 µL/mL) for 45 min at room temperature.  Platelet 
 47 
spreading was imaged as previously described
99
, and only platelets with both GFP and 
actin staining were visualized.  Platelet surface area was measured in pixels using Image 
J software (National Institutes of Health, Bethesda, MD) particle analysis.  Particles of 
sizes from 250 to 4050 pixels, which represented those well-separated platelets, were 
measured.  
 
Platelet stimulation assays 
Platelet stimulation assays quantified by flow ctytometric analysis were perfomed as 
previously described
99
.  Platelet-rich plasma (PRP) was diluted to 2.5 x 10
7
 platelets per 
mL in modified Tyrode’s buffer, and 2.5 x 10
6
 platelets were stimulated with varying 
concentrations of convulxin for 10 min at 37°C in the presence of PE-conjugated anti-
murine P-selectin antibody (2 µL/mL, BD Biosciences) and 1 mM CaCl2 and MgCl2.  In 
time-course assays, 2.5 x 10
6
 platelets were stimulated were stimulated with 10 nM 
convulxin (Alexis) or 10 µg/mL CRP for the time indicated in the presence of Alexa-
Fluor 647-conjugated fibrinogen, and the reaction was stopped by addition of 1% 
paraformaldehyde for 5 min followed by washing.  In time course assays using JON/A 
antibody binding, platelets were stimulated with 10 nM convulxin for the time indicated 
at room temperature, and the reaction was stopped by addition of 1% paraformaldehyde 
for 5 min followed by washing. Platelets were then stained by addition of PE-conjugated 
JON/A antibody (10 µL/mL) for 30 min at room temperature. Fibrinogen and antibody 
binding were measured with a FACSort (BD Biosciences, San Jose, CA), and the data 
were analyzed with FlowJo 6.3.1 software (Tree Star, Ashland, OR).  
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Ca
2+
 mobilization assays 
RBL-2H3 cells were labeled with Fura-2 AM (Molecular Probes, Eugene OR), and 
calcium signaling was detected as previously described
58
.  Briefly, RBL-2H3 cells 
transfected with lentivirus driving expression of WT or PD GPVI or vector alone were 
grown to confluence in a 10 cm culture dish and many cells had detached from the dish 
surface.  These non-adherent RBL-2H3 cells are perfectly viable.  Floating and adherent 
cells were isolated by successive aspiration, washed in RHB medium (RPMI 1640 
[Invitrogen] containing 25 mM HEPES and 1 mg/mL BSA), and resuspended to a 
concentration of 2 x 10
7
 cells per mL.  Fura-2 AM was added to the cell suspension at a 
final concentration of 4 µg/mL and incubated at 37 °C in 5% CO2 for 30 min.  Cells were 
washed twice in RHB medium and resuspended in RHB medium at a concentration of 2 x 
10
6
 cells per mL.  Aliquots of 1.4 mL of labeled cells were analyzed in a Fluorescence 
Spectrometer under stirring conditions following addition of agonist. 
 
Fabrication of microfluidic devices, collagen patterning, and whole blood flow assay 
Fabrication of microfluidic devices and microfluidic collagen patterning was performed 
as previously described 
39
.  Channels were initially filled with 1 mg/mL BSA in HBS to 
ensure that no bubbles were trapped in the channel.  Whole blood from reconstituted 
mice was collected retro-orbitally as described above.  Blood was incubated with JAQ-1 
antibody at 25 µg/mL for 10 min, to block any wild-type mouse GPVI on platelets 
derived from host precursors that escaped bone marrow ablation, and with 5 µg/mL 
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Leo.H4 monoclonal antibody, to prevent aggregate formation for ease of analysis.  Whole 
blood from lyn-/- or fyn-/-  mice and wild-type controls was collected retro-orbitally in 
heparinized capillary tubes, labeled with Alexa-Fluor 488-conjugated CD41 antibody, 
and incubated with 5 µg/mL Leo.H4.  A volume of 70 µL of whole blood was placed on 
the inlet of the device and withdrawn by a syringe pump (Harvard Apparatus PHD 2000, 
Holliston, MA) for up to 4 min at flow rates of 5 µL/min to achieve a full channel width-
averaged wall shear rate of chan!  = 1000 s
-1
.   
 
Image capture and analysis 
The adhesion of GFP+ platelets or fluorescently labeled platelets was monitored 
continuously by epifluorescence microscopy.  For blood from reconstituted animals, 
images were captured continuously with a 60-200 ms exposure time depending on the 
percentage of GFP+ platelets in each mouse at an interval of 100 ms using Slidebook 
software (Intelligent Imaging Innovations).  Every new rolling platelet that appeared was 
tracked in subsequent frames to determine if it ultimately adhered firmly to the collagen 
surface or if it continued to roll but did not adhere.  All analyses were performed with the 
observer blinded to the identity of the sample. All image stacks were analyzed frame-by-
frame in Slidebook.  Any platelet that was captured by fluorescent imaging was presumed 
to be rolling along the collagen surface, as non-rolling GFP+ platelets, leukocytes, and 
red blood cells moved too fast to be visualized.  Each frame was analyzed to determine if 
a new platelet began to roll on the patterned collagen surface. Firmly adherent platelets 
were defined as ones that did not change position for at least 30 frames.  Platelets that 
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came in contact with the wall of the flow chamber were not counted.  Platelets that rolled 
as a pre-formed clump or adhered to pre-existing platelet clumps and not to the collagen 
surface directly were not counted.  Each experiment was only analyzed as long as 
individual platelet-collagen interactions could be distinguished.  In determining the 
number of frames each adherent platelet spent rolling, the last frame before the platelet 
changed position for a final time was counted.  Thus, a platelet that was permanently 
adhered by the first frame in which it was observed was counted as rolling for zero 
frames, and the rolling time consisted only of the interval before the frame in which the 
platelet appeared.  The adhesive efficiency for each image stack was determined by 
calculating a / (a + r), where a equals the number of platelets that permanently adhere 
and r equals the number of platelets that roll along collagen but do not adhere.  The time 
each adherent platelet spent in the rolling phase was calculated as (F)(Ex) + (F + 1)(Int), 
where F equals the number of frames the platelet spent rolling, Ex equals the exposure 
time per frame, and Int equals the interval time between captures, which was 100 ms for 
all experiments.    
Images were captured using a CCD camera (C9300-201 Hamamatsu, 
Bridgewater, NJ) mounted on an inverted microscope (Nikon Eclipse TE2000-U, 
Melville, NY) with a 300 W Xenon lamp (Perkin Elmer Optoelectronics, Freemont, CA) 
through a Lambda DG-4 high-speed filter changer (Sutter Instruments, Novato, CA) used 
at 470 nm Ex / 525 nm Em.  For blood flow experiments from Lyn-/- or Fyn-/- mice or 
wild-type controls, the collagen patch was defined using Image J software (National 
Institutes of Health, Bethesda, MD).  The average background of the upstream region was 
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calculated for each column and those values were subtracted from the reaction zone pixel 
values to correct for background gradients across the width of the channel.  Surface 
coverage was calculated by dividing the area of pixels with a value greater than zero by 
the area of the collagen patch.   
 
Production of GST-fusion proteins and expression of recombinant SFKs and Nef 
GST fusion proteins of the GPVI C-tail were prepared from cDNA encoding the WT or 
PD GPVI sequence beginning from Glu269 to the terminal Ser residue using forward 
primer 5’-TAGAATTCGAGGACTGGCACAGCCGGAGGAA-3’ and reverse primer 
5’-TACTCGAGTCATGAACATAACCCGCGGCTGTG-3’.  Fragments were subcloned 
into EcoRI/XhoI sites of pGEX4T-1, and proteins were expressed in E. coli according to 
manufacturer instructions, purified with glutathione agarose (Amersham Biosciences, 
Piscataway, NJ).  Human Hck, Lyn, and c-Src were expressed in Sf9 insect cells and 
purified to homogeneity as previously described
103
.  The C-terminal sequence of each 
SFK was modified to Tyr-Glu-Glu-Ile-Pro, which promotes autophosphorylation of the 
tail tyrosine and permits high yield purification of the downregulated form of each 
kinase
103
.  The SF2 allele of HIV-1 Nef was expressed in bacteria and purified as 
previously described
103
.   
 
Phage display  
The phage-displayed SH3 domain library panning onto purified target proteins was 
performed as previously described
101
.  Briefly, 6-well tissue culture plates (Cellstar) were 
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coated with 20 !g/mL bacterially expressed purified GST fusion proteins of the GPVI C-
tail and the GPVI C-tail lacking the PD sequence or, in control experiments, GST protein 
alone (1.5 mL per well) in 50 mM Na-carbonate buffer pH 9.6 overnight at 4ºC.  The 
subsequent steps were performed at room temperature.  The plates were washed 3 times 
with 2 mL of TBS-T buffer (Tris-buffered saline [TBS] supplemented with 0.05% Tween 
20) and incubated with blocking solution (5% non-fat milk in TBS-T) for 2h, followed by 
incubation with the mixture of human SH3 library-displaying phages (109-1010 pfu/well) 
prepared in TBS-T and supplemented with 2.5% of non-fat milk for 2 h.  Subsequently, 
the phage mixture was removed and plates were washed 4 times with 2 mL of TBS-T.  
The infection of TG1 bacteria by phages that remained bound to GPVI C-tail proteins or 
GST alone was carried out by adding 1 mL of log-phased cells (OD600 = 0.5-0.6) to each 
well followed by incubation at 37ºC for 1h.  Subsequently, different dilutions of infected 
TG1 (1:1, 1:10, 1:100, and 1:1000) were seeded onto ampicillin-containing LB plates.  
The next day, the resultant colony numbers from WT GPVI C-tail and from PD GPVI C-
tail were compared to the number of colonies obtained from the control (GST alone) 
plate.  WT GPVI C-tail-interacting SH3 domains were identified by performing a 
sequencing reaction (sequencing primer 5’-CCTATTGCCTACGGCAGCC-3’) on the 
SH3 domain-encoding phagemides that were isolated from individual bacterial colonies. 
 
Immunoprecipitations from platelet or RBL-2H3 cell lysate 
Blood was collected from 5 healthy donors into 30 or 60 mL syringes containing 5 or 10 
mL of acid citrate dextrose.  Platelets were isolated from platelet-rich plasma by 
 53 
centrifugation in the presence of 1 U/mL apyrase and 1 µM prostacyclin and washed 
once in platelet wash buffer (10 mM HEPES, 1 mM EDTA, 150 mM NaCl, pH 6.0) 
before resuspending in modified Tyrode’s buffer.  6 x 10
8
 washed platelets were 
stimulated with 10 nM convulxin or left unstimulated at 37º C with stirring, and reactions 
were terminated with addition of 5x lysis buffer (1% NP-40, 50 mM Tris pH 7.4, 150 
mM NaCl, 2 mM EDTA final concentration) with a 1:50 dilution of EDTA-free protease 
inhibitor cocktail (Roche Diagnostics, Indianapolis, IN) and a 1:100 dilution of HaltTM 
phosphatase inhibitor cocktail (Thermo Scientific, Rockford, IL).  Transfected RBL-2H3 
cells were incubated in RPMI at 37ºC for 30 min at a concentration of 1 x 10
7
 cells per 
mL.  6 x 10
6
 RBL-2H3 cells were stimulated with 1 nM convulxin or left unstimulated at 
37º C with stirring, and reactions were terminated with addition of an equal volume of 
ice-cold 2x NP40/dodecyl maltoside lysis buffer (1.6% NP-40, 2% dodecyl maltoside, 20 
mM Tris, pH 7.5, 300 mM NaCl, 4 mM EDTA, 2 mM dithiothreitol)
105
, with protease 
and phosphatase inhibitors as described above.  Samples were lysed for 1 h at 4ºC, and 
insoluble material was pelleted by centrifugation at 15,000 g for 20 min.  For GST-fusion 
immunoprecipitation, lysate was incubated with glutathione-sepharose beads conjugated 
with GPVI GST-fusion protein.  For GPVI immunoprecipitation, lysate was incubated 
with 5 µg/mL HY101 monoclonal antibody or 5 µg/mL mouse IgG for 2 h at 4ºC before 
addition of protein-A sepharose and overnight incubation with rocking.  Sepharose beads 
were pelleted and washed 4 times for 5 min in 1x lysis buffer before addition of Laemmli 
sample buffer with 2.5% $-mercaptoethanol and boiling for 10 min.  Samples were run 
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on 4-12% v/v gradient SDS-polyacrylamide using MOPS electrophoresis buffer, 
transferred to PVDF membranes, blocked, and probed with antibody. 
 
In vitro kinase assays 
Production of recombinant HIV-1 Nef and tyrosine kinase assays were performed in 384-
well plates using the Z’-Lyte kinase assay system and the Tyr2 peptide substrate 
(Invitrogen) as previously described
103
.  Briefly, to assess the effect of GPVI compared to 
Nef on SFK activity, Hck (20 ng), Lyn (50 ng), or c-Src (50 ng) was incubated at room 
temperature for 5 min with increasing molar concentrations of GST-WT GPVI, GST–PD 
GPVI, or Nef.  Purified GST-fusion proteins were dialyzed to remove free glutathione 
prior to use in in vitro kinase assays.  ATP (100 !M final) and Tyr2 substrate (1 !M 
final) were then added to the reaction, and samples were incubated for 1 h (45 min for 
Hck).  Development reagent, which contains a protease that digests non-phosphorylated 
peptide, was then added, and samples were incubated for an additional 60 min before 
termination of the reaction with stop reagent.  Fluorescence was assayed, based on FRET 
between coumarin and fluorescein in the phosphorylated (uncleaved) substrate peptide 
only.  Raw fluorescence values were corrected for background, based on a 0% 
phosphorylation (no ATP) negative control, and reaction endpoints were calculated as 
emission ratios of coumarin fluorescence divided by the fluorescein FRET signal.  These 
ratios were then normalized to the ratio obtained with a 100% phosphorylation control 
peptide.  Each condition was assayed in quadruplicate, and results are presented as the 
mean ± SD. 
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Statistics 
P values were calculated using an unpaired two-tailed Student’s t test assuming unequal 
variance. 
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Figure 2-1.  Expression of wild-type GPVI receptors and GPVI receptors lacking 
the intracellular PRD in GPVI-deficient mouse platelets using retroviral vectors.   
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Figure 2-1 (cont’d).  Expression of wild-type GPVI receptors and GPVI receptors 
lacking the intracellular PRD in GPVI-deficient mouse platelets using retroviral 
vectors. 
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Figure 2-1.  Expression of wild-type GPVI receptors and GPVI receptors lacking 
the intracellular PRD in GPVI-deficient mouse platelets using retroviral vectors.   
A. Alignment of the predicted transmembrane and intracellular amino acid sequences 
from opossum (d), mouse (m), and human (h) genes encoding the GPVI receptor, the 
homologous and paralogous human Fc alpha receptor (Fc#RI), and the mouse paired Ig-
like receptor (PIR)a.  The amino acids shown in orange are involved in coupling of the 
receptor to the transmembrane signaling adaptor FcR!.  The amino acids shown in red 
constitute a binding motif for SH3 domains.  Note the lack of the GPVI PRD in 
homologous immune receptors.  B. The amino acid sequences of the cytoplasmic tails of 
the wild-type human GPVI (WT GPVI) and mutant GPVI lacking the proline-rich region 
of the cytoplasmic tail (PD GPVI) are shown. The sequence of the cytoplasmic tail of 
human PD GPVI lacked 7 amino acid residues unique to the PRD and was identical to 
that shown by Suzuki-Inoue et al. to no longer bind SFK SH3 domains
95
.  C. Retroviral 
co-expression of GPVI receptors and GFP in GPVI-deficient mouse platelets.  Retroviral 
vectors were used to co-express GFP only (vector), or GFP with either WT GPVI or PD 
GPVI, in GPVI-deficient fetal liver cells that were subsequently used to reconstitute 
lethally irradiated mice.  Shown are GFP and surface GPVI expression in the platelets of 
animals reconstituted with cells exposed to empty vector (vector), vector driving 
expression of WT GPVI, vector driving expression of PD GPVI, and human platelets.  
GFP+ platelets expressing surface WT GPVI and PD GPVI are shown in red boxes.      
D. Expression levels of human GPVI on mouse platelets.  Shown are histograms of 
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surface GPVI in GFP-positive platelets from the indicated reconstituted mice compared 
to GPVI on human platelets.  
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Figure 2-2.  Loss of the GPVI PRD does not alter sustained GPVI receptor signaling 
in platelets. 
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Figure 2-2.  Loss of the GPVI PRD does not alter sustained GPVI receptor signaling 
in platelets.  A. Platelet activation mediated by WT and PD GPVI signaling.  Platelets 
from GPVI-deficient mice expressing WT GPVI or PD GPVI receptors were stimulated 
with the indicated concentrations of convulxin for 10 min, and activation was measured 
using flow cytometry to detect the expression of surface P-selectin in GFP+, GPVI-
expressing platelets.  AYP indicates exposure to the PAR4 agonist peptide AYPGKF.    
B. Dose-response curve of platelet activation mediated by WT and PD GPVI signaling.  
C. Platelet spreading on collagen mediated by WT or PD GPVI.  Platelets from the 
indicated mice were incubated for 45 min on immobilized type-I collagen, and spreading 
was visualized by staining with Alexa-Fluor 594-conjugated phalloidin to detect cellular 
actin.  GFP expression was simultaneously measured to identify platelets derived from 
vector-transduced precursors.  D. Quantitation of platelet spreading driven by WT GPVI 
or PD GPVI, depicted in panel C.  The area occupied by adherent platelets was measured 
using the Image J program.  n = 100-300 individual platelets from 2-3 different animals 
analyzed for WT or PD GPVI or vector control. 
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Figure 2-3.  The intracellular PRD is required for rapid platelet activation by GPVI 
receptors.     
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Figure 2-3.  The intracellular PRD is required for rapid platelet activation by GPVI 
receptors.  A. Time course of platelet fibrinogen binding by WT and PD GPVI-
expressing platelets following convulxin stimulation.  Platelets were stimulated with 10 
nM convulxin in the presence of Alexa-Fluor 647-conjugated fibrinogen for times 
indicated, fixed, and analyzed by flow cytometry.  B. Time course of JON-A binding 
following 10 nM convulxin stimulation.   C. Time course of fibrinogen binding following 
stimulation with 10 µg/mL CRP.  In all experiments only GFP+, GPVI-expressing 
platelets were analyzed.  * = P <0.05, ** = P <0.01; error bars indicate mean ± SD; n = 
3-6 experiments for each time point indicated, using 4 animals for WT or PD GPVI.  
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Figure 2-4.  Time course analysis of P-selectin expression and fibrinogen binding 
following convulxin stimulation in wild-type platelets. 
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Figure 2-4.  Time course analysis of P-selectin expression and fibrinogen binding 
following convulxin stimulation in wild-type platelets.  A. Time course of P-selectin 
expression following convulxin stimulation.  Wild-type mouse platelets were stimulated 
with 10 nM convulxin for times indicated in the presence of antibody against P-selectin, 
and P-selectin expression was determined by flow cytometry.  B. Time course of platelet 
fibrinogen binding following convulxin stimulation.  Platelets were stimulated with 10 
nM convulxin in the presence of Alexa-Fluor 647-conjugated fibrinogen for times 
indicated, fixed, and analyzed by flow cytometry.  P values were calculated between time 
points indicated; error bars indicate mean ± SD; n = 4-8 experiments for each time point 
indicated, using 4 animals. 
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Figure 2-5.  PD GPVI receptors exhibit delayed Syk phosphorylation and calcium 
signaling.  
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Figure 2-5.  PD GPVI receptors exhibit delayed Syk phosphorylation and calcium 
signaling.  A. Lentiviral vectors were used to express WT GPVI or PD GPVI or vector 
alone (vector) in RBL-2H3 cells, and surface expression of GPVI was detected by flow 
cytometry.  B. Time course of GPVI-mediated activation of Syk following convulxin 
stimulation in WT GPVI and PD GPVI-expressing RBL-2H3 cells.  GPVI-expressing 
RBL-2H3 cells were stimulated with convulxin for the time periods indicated, and whole 
cell lysate was analyzed by immunoblotting (WB) with antibodies against activated Syk 
(pSyk) and total Syk.  C. Ca2+ mobilization in RBL-2H3 cells expressing WT and PD 
GPVI and vector control.  Cells were loaded with the Ca2+-sensitive fluorophore Fura-2 
AM and stimulated with 1 nM convulxin.  Intracellular Ca2+ mobilization was measured 
by the ratio of Fura-2 emissions in a fluorimeter.  Curves from representative experiments 
are shown; n = 3 measurements. 
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Figure 2-6.  Tracking rolling and adhesion of GFP+/GPVI+ platelets to collagen 
under flow. 
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Figure 2-6.  Tracking rolling and adhesion of GFP+/GPVI+ platelets to collagen 
under flow.  Measurement of platelet adhesion efficiency during flow over a collagen 
coated surface.  Shown is an example of sequential images taken with a 75 ms exposure 
time during flow of whole blood containing WT GPVI-expressing platelets over a type-I 
collagen-coated surface.  Blood from reconstituted mice was flowed over a patterned 
type-I collagen strip at a shear rate of 1000 s
-1
, and fluorescent images were taken every 
100 ms to follow the interaction of GFP+ platelets with collagen under flow.  Each 
platelet that appears on the collagen strip was tracked to determine if it remained adherent 
(red circles) or did not remain adherent (blue circles). Adhesive efficiency was 
determined by a / (a + r), where a = # of platelets that permanently adhere and r = # of 
platelets that roll along collagen but do not adhere.  The direction of flow and 
translocation of platelets is from left to right. 
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Figure 2-7.  The GPVI PRD is required for efficient platelet adhesion to collagen 
under flow. 
 
 
 71 
Figure 2-7.  The GPVI PRD is required for efficient platelet adhesion to collagen 
under flow.  A. Adhesive efficiency to collagen under flow of WT or PD GPVI-
expressing platelets or vector control platelets.  B. Rolling times on collagen for WT or 
PD GPVI platelets.  The time each adherent platelet spent in the rolling phase was 
calculated based on the number of frames during which each platelet changed position.  
B. (i) Rolling times are shown divided into terciles (1st, shortest third of rolling times in 
each group; 2nd, middle third of rolling times in each group; 3rd, longest third of rolling 
times in each group).  B. (ii) Percentage rolling times < 350 ms, 350–700 ms, and > 700 
ms. The same adherent platelets were analyzed in panels (i) and (ii). ** = P < 0.01; error 
bars indicate mean ± SD; 3-5 movies using 3-4 animals for each GPVI variant or vector 
control were analyzed in a blinded fashion; n = total number of adherent platelets 
analyzed. 
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Figure 2-8.  The GPVI PRD preferentially binds the SH3 domains of the SFKs Lyn 
and Hck. 
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Figure 2-8.  The GPVI PRD preferentially binds the SH3 domains of the SFKs Lyn 
and Hck.  A. Shown are the amino acid sequences of the cytoplasmic tail of WT GPVI 
and PD GPVI expressed as GST-fusion proteins.  B. Binding of SH3 domain-containing 
proteins from platelet lysate is dependent on the GPVI PRD.  Washed human platelets 
were lysed, and platelet proteins were precipitated with either GST-WT GPVI or GST-
PD GPVI bound to glutathione beads, resolved by SDS-PAGE, and analyzed by 
immunoblotting (WB) for Lyn, Fyn, or GST.  C. Phage display screening of WT or PD 
GPVI GST-fusion protein binding to human SH3 domains, an unbiased method in which 
all SH3 domains compete with each other for binding to the target protein.  SH3 domain-
expressing phages captured by GST-GPVI constructs or plain GST were used to infect E. 
coli TG1 cells and plated as 10-fold dilutions onto ampicillin plates.  Enrichment of SH3 
displaying phages bound to the WT GPVI receptor was approximately 1000-fold 
compared to that bound to PD GPVI or GST alone.  D. Lyn constitutively associates with 
GPVI in unstimulated platelets.  Washed human platelets were left unstimulated or 
stimulated with 3 nM convulxin for 15 s, lysed, and proteins immunoprecipitated (IP) 
with GPVI were resolved by SDS-PAGE and analyzed by immunoblotting (WB) for Lyn, 
Fyn, Src, Btk, FcR!, or GPVI.  An immunoblot of whole cell lysate (WCL), loaded at 1% 
of GPVI IP input, and one of mouse IgG control IP are also shown.  Blots depicted are 
representative of 3 independent experiments. 
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Table 2-I.  The GPVI cytoplasmic tail preferentially binds the SFKs Lyn and Hck.   
                                     # of clones 
SH3 domain 
Screen 
#1 
Screen 
#2 
Screen 
#3 Total 
Lyn 
4/8 
clones 
10/24 
clones 
2/16 
clones 
16/48 
clones 
Hck 
1/8 
clones 
10/24 
clones 
8/16 
clones 
19/48 
clones 
Fyn 
1/8 
clones 
1/24 
clones 
0/16 
clones 
2/48 
clones 
Btk 
1/8 
clones 
1/24 
clones 
2/16 
clones 
4/48 
clones 
Yes 
1/8 
clones 
0/24 
clones 
2/16 
clones 
3/48 
clones 
Src 
0/8 
clones 
0/24 
clones 
0/16 
clones 
0/48 
clones 
CrkL 
0/8 
clones 
1/24 
clones 
0/16 
clones 
1/48 
clones 
Intersectin 1 3rd SH3 
domain 
0/8 
clones 
1/24 
clones 
2/16 
clones 
3/48 
clones 
 
 
Table 2-I.  The GPVI cytoplasmic tail preferentially binds the SFKs Lyn and Hck.   
The identity of the SH3 domains bound by GST-WT GPVI proteins was determined by 
sequencing the inserts of the selected phage clones after a single round of affinity 
selection.  Shown are sequencing results of bacterial clones containing the phagemide 
encoding the corresponding SH3 domain bound to WT GPVI.  Results demonstrate GPVI 
intracellular tail binding preference for SFKs, specifically Lyn and Hck 
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Figure 2-9.  GPVI directly activates Lyn and Hck in a PRD-dependent manner. 
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Figure 2-9.  GPVI directly activates Lyn and Hck in a PRD-dependent manner. 
Recombinant Hck (panel A), Lyn (panel B), and c-Src (panel C) were purified from Sf9 
insect cells in an inactive state and assayed for kinase activity with a peptide substrate in 
vitro in the presence of increasing concentrations of purified GST-WT GPVI, GST-PD 
GPVI, or recombinant HIV-1 Nef.  Each condition was repeated in quadruplicate, and the 
extent of phosphorylation is expressed as mean percent phosphorylation relative to a 
control phosphopeptide ± SD.  The results shown are representative of 2 independent 
experiments. 
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Figure 2-10.  GPVI-bound Lyn is held in the active state in unstimulated platelets. 
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Figure 2-10.  GPVI-bound Lyn is held in the active state in unstimulated platelets. 
Washed human platelets were left unstimulated or stimulated with 3 nM convulxin for 15 
s, lysed, and proteins immunoprecipitated (IP) with GPVI were immunoblotted (WB) 
with phosphospecific antibodies for Lyn.  pY396 indicates Lyn phosphorylated at the 
activation loop, and pY507 indicates Lyn phosphorylated at the negative regulatory site.  
Phospho-Lyn Y396 antibody reacts with other SFKs phosphorylated at their activation 
loop, but the characteristic doublet at 53 kD and 56 kD identifies Lyn as the predominant 
species. Probing with 4G10 was used to detect phosphorylated FcR! chain, compared to 
total FcR! chain, that co-immunoprecipitated with GPVI.  An immunoblot of whole cell 
lysate (WCL), loaded at 1% of GPVI immunoprecipitation input, is also shown.  Blots 
depicted are representative of 3 independent experiments. 
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Figure 2-11.  Lyn- and Fyn-deficient platelet activation following convulxin 
stimulation.  
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Figure 2-11 (cont’d).  Lyn- and Fyn-deficient platelet activation following convulxin 
stimulation.  
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Figure 2-11.  Lyn- and Fyn-deficient platelet activation following convulxin 
stimulation.  A. Platelets from Lyn-/- mice or wild-type littermate controls (WT) were 
stimulated with the indicated concentrations of convulxin for 10 min, and P-selectin 
expression was determined by flow cytometry.  B. Time course of platelet fibrinogen 
binding following convulxin stimulation.  Platelets were stimulated with 10 nM 
convulxin in the presence of Alexa-Fluor 647-conjugated fibrinogen for times indicated, 
fixed, and analyzed by flow cytometry. * = P <0.05, ** = P <0.01, *** = P <0.005; error 
bars indicate mean ± SD; n = 4-6 experiments using 3 mice of each genotype for each 
concentration of convulxin or time point.  C. Platelets from fyn-/- mice or wild-type 
littermate controls (WT) were stimulated with the indicated concentrations of convulxin 
for 10 min, and P-selectin expression was determined by flow cytometry.  Bars indicate 
% P-selectin positive platelets.  D. Time course of platelet fibrinogen binding following 
convulxin stimulation.  Platelets were stimulated with 10 nM convulxin in the presence of 
Alexa-Fluor 647-conjugated fibrinogen for times indicated, fixed, and analyzed by flow 
cytometry.  Bars indicate mean fluorescent intensity (MFI) of fibrinogen binding.  * = P 
<0.05, ** = P <0.01, *** = P <0.005; error bars indicate mean ± SD; n = 4-6 experiments 
using 3 mice of each genotype for each concentration of convulxin or time point. 
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Figure 2-12.  Lyn-deficient platelets exhibit defective adhesion to collagen under 
flow.  
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Figure 2-12.  Lyn-deficient platelets exhibit defective adhesion to collagen under 
flow.   A. Blood from Lyn-/-, Fyn-/-, or wild-type control animals was flowed over a 
patterned type-I collagen strip at a shear rate of 1000 s
-1
.  Images depict adhesion of 
fluorescently labeled platelets after 5 min of flow.  The direction of flow is from left to 
right.  B. Quantitation of percent of surface area coverage following 5 minutes of flow.  
*** = P < 0.005 for surface area coverage between WT and Lyn-/- platelets and between 
Fyn-/- and Lyn-/- platelets; error bars indicate mean ± SD; n = 6-8 experiments using 4 
mice of each genotype.  
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Figure 2-13.  Priming of Lyn by the GPVI PRD drives rapid signal transduction 
following receptor ligation. 
 
Figure 2-13.  Priming of Lyn by the GPVI PRD drives rapid signal transduction 
following receptor ligation.  In this model, Lyn is held in an activated state when 
constitutively bound to GPVI through displacement of the Lyn SH3 domain (light green) 
by the GPVI PRD (light red).  Premature, ligand-independent receptor signaling is 
prevented by sequestration of the GPVI-associated FcR! chain (dark green) within the 
lipid bi-layer, keeping ITAM domains (light blue) inaccessible to activated Lyn prior to 
receptor ligation
112
.  Following GPVI-collagen binding, the FcR! chain is released from 
the membrane by clustering or mechanical shear forces, allowing GPVI-bound, activated 
Lyn to phosphorylate the FcR! ITAM.  ITAM phosphorylation results in recruitment of 
Syk (purple) and initiation of the downstream GPVI signaling cascade. 
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Chapter 3—In contrast to mammalian platelets, avian thrombocytes do not form 
aggregates on collagen under arterial flow conditions 
 
Summary 
Specific cellular and molecular mechanisms exist within platelets to orchestrate the 
coordinated action of aggregate formation over collagen during hemodynamic flow. Both 
mammals and birds have high-pressure vascular systems, with similar flow rates and 
fluid shear forces.  In birds, nucleated thrombocytes that are 3-5 times the diameter of 
platelets, and approximately 10-fold less numerous, are believed to play a hemostatic role 
analogous to that of platelets.  However, it is unknown whether avian thrombocytes 
mediate aggregate formation under high shear in a manner similar to platelets.  Using 
transcriptional profiling, we find that avian thrombocytes express most of the signaling 
receptors and pathways described in platelets.  Flow of PPACK-anticoagulated chicken 
whole blood over chicken collagen at high shear results in thrombocyte rolling and firm 
adhesion, but thrombocytes covered significantly less surface area compared to human 
platelets and failed to form 3-dimensional aggregates.  We describe molecular differences 
between platelets and thrombocytes that may explain the inability of thrombocytes to 
form aggregates under flow and suggest that vaso-occlusive arterial thrombosis may be a 
uniquely mammalian phenomenon that provided an evolutionary advantage in response 
to trauma but now underlies the basis of human cardiovascular disease and death. 
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Introduction 
Acute myocardial infarction results from coronary artery occlusion by a platelet thrombus 
formed under high shear, most often following rupture of a nonstenotic atherosclerotic 
plaque
5,6
.  Platelet-driven thrombosis is especially important in the arterial system, 
particularly in the high shear environment of stenotic coronary arteries 
1,120
.  Platelet 
aggregate formation under hemodynamic shear is highly efficient, and inhibiting this 
process is a basis for treatment of cardiovascular disease.  Improved understanding of the 
pathological mechanisms underlying platelet aggregate formation at the site of vessel 
injury will advance our knowledge and treatment of cardiovascular disease. 
 The mechanisms by which platelets adhere and aggregate under hemodynamic 
conditions are essential for mammalian hemostasis and thrombosis and have been 
exceptionally well studied
85
.  Hemostasis, the cessation of bleeding, is a requirement of 
any organism that utilizes blood circulation for tissue oxygenation and removal of waste 
products.  All essential mammalian blood coagulation factors are conserved in primitive 
non-mammalian vertebrates such as zebrafish
121
.  While hemostasis is a necessity to 
mammalian and non-mammalian species alike, megakaryocytes and non-nucleated 
platelets are exclusive to mammals.  All other vertebrates have nucleated thrombocytes, 
instead of platelets, as hemostatic effector cells.  Significantly less is understood of the 
function of thrombocytes, compared to that of platelets. 
Thrombocytes found in non-mammalian vertebrates are nucleated, ovoid-shaped, 
and formed from diploid precursors in the bone marrow. Unlike more primitive 
vertebrates, such as the zebrafish or reptilian species, avian species have a highly 
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developed cardiovascular system with a high cardiac output and blood pressures that can 
exceed those in mammalian systems
122
.  Therefore, the hemodynamic forces that 
necessitate efficient hemostasis in mammals must also be present in birds.  Circulating 
thrombocytes are larger than platelets and similar in size to lymphocytes, about 6-8 µm in 
diameter.  In chicken blood, there are approximately 20-60,000 thrombocytes per µL, a 
significantly lower concentration than that of mammalian platelets
123,124
.  
The function of thrombocytes in serving as specialized hemostatic cells is 
believed to be analogous to that of platelets, but evidence in support of this claim is 
limited and consists almost entirely of in vitro data.  Avian thrombocytes express #2b$3 
integrin and aggregate through binding plasma fibrinogen in response to thrombin and 5-
HT stimulation
125-127
.  In contrast to platelets, thrombocytes have not been demonstrated 
to aggregate in response to ADP or epinephrine, although ADP may cause thrombocyte 
shape change
125,128
.  Thrombocytes secrete granule contents, including 5-HT, following 
stimulation and contain a surface-connected canalicular system membrane component, 
also found in platelets
129-131
.  Additionally, thrombocytes actively phagocytose Gram-
positive and -negative bacteria and have been proposed to serve a broader immunologic 
function compared to that of platelets
124,132
. 
The fact that megakaryocytes and platelets are unique to mammals suggests there 
is some important aspect of mammalian biology and evolution—perhaps the need for 
more efficient hemostasis in response to trauma—that benefitted from the use of 
platelets, compared to thrombocytes, as hemostatic cells.  However, if this hypothesis is 
correct—that platelets confer a superior hemostatic response to the organism—then what 
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functions of platelets are exceptional and cannot be performed by thrombocytes?  It is 
intriguing that platelets are not required for any known element of hemostasis that is only 
found in mammals.   
The existence of thrombocytes in avian species with high-pressure vascular 
systems presents an opportunity to test the conservation of basic elements of cellular 
hemostasis between platelets and thrombocytes.  Our initial interest in avian thrombocyte 
biology began from the finding that thrombocytes do not contain an ortholog of the 
platelet collagen receptor glycoprotein (GP) VI detectable by BLAST search (see Chapter 
2), while many other platelet-specific receptors have definitive chicken orthologs.  We 
were surprised to discover studies demonstrating that chicken thrombocytes aggregate in 
response to collagen, a GPVI-dependent process in mammals
127,130
.  Through collagen-
induced platelet activation, GPVI is required for the transition of a rolling platelet to a 
firmly adherent platelet during flow on a collagen surface (see Chapter 1).  Our findings 
in the previous chapter demonstrate that GPVI is molecularly specialized to rapidly 
activate platelets under conditions of hemodynamic flow.  Can thrombocytes also activate 
and firmly adhere to collagen under arterial shear conditions? 
Using transcriptional profile analysis, we determine that thrombocytes 
specifically express the receptors associated with hemostatic function and shear-resistant 
adhesion in platelets.  Signaling studies confirm that thrombocytes are potently activated 
by collagen.  Collagen signaling in the thrombocyte uses an immune receptor pathway 
analogous to that of GPVI.   During flow of chicken whole blood in the presence of 
thrombin inhibition, we observe thrombocyte rolling and integrin-dependent firm 
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adhesion.  However, there is significantly less surface coverage compared to that 
exhibited by platelets and a striking absence of 3-dimensional aggregate formation.  We 
demonstrate that specific molecular mechanisms that have been adopted by the platelet to 
promote aggregate formation under shear, such as a high density of #2b$3 integrin, are 
absent in the thrombocyte.  These studies suggest that the ability to rapidly form 3-
dimensional aggregates under arterial shear is exclusive to platelets.  Platelet-mediated 
occlusive thrombus formation may represent a distinct quality of mammalian hemostasis 
not present in other species that also have a high-pressure system. 
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Results 
Chicken thrombocytes specifically express genes associated with platelet function. 
Thrombocytes in avian species are believed to express many platelet-specific proteins 
and function analogously to platelets in mammalian systems, yet a thorough 
transcriptional profile analysis has not been performed.   We wished to complete a gene-
expression profile analysis of chicken thrombocytes to determine if they contain 
transcripts associated with hemostatic function and if this expression is restricted only to 
thrombocytes.  Based on their expression of #2b$3 integrin, thrombocytes could be 
isolated from chicken plasma preps by staining with AP-2 mAb, which cross-reacts with 
both chicken and human #2b$3
123
 (Fig. 3-1A).  On average, chicken plasma preps 
contained about 50-70% thrombocytes, with the rest presumably representing leukocytes 
(Fig. 3-1A).  Using cell sorting based on positive and negative cell markers, we isolated 
pure populations of chicken thrombocytes and lymphocytes (Fig. 3-1B).  Gene-
expression analysis on the Affymetrix chicken chip revealed that thrombocytes, and not 
lymphocytes, significantly upregulate genes that are known to have a specific role in 
platelet function, including the VonWillebrand factor receptors GPIb and GPIX, integrins 
$1, $3, #2, and #V, the thrombin receptor protease-activated receptor (PAR) 1, the ADP 
receptors P2X1 and P2Y1, and the serotonin receptor HTR2A (Table 3-I).  The fact that this 
list was not exhaustive for platelet genes is at least partially due to incomplete annotation 
of the chicken genome and/or lack of representation on the Affymetrix chicken gene chip.  
These limitations notwithstanding, transcriptional profile analysis confirms that chicken 
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thrombocytes are specialized among hematopoietic cells to serve a hemostatic function in 
the organism.   
 
Chicken thrombocytes are strongly activated by thrombin and collagen. 
In vivo, following vessel injury, thrombin from tissue factor release and collagen 
exposure in the subendothelium are the two primary activators of platelets (see Fig. 1-1).  
We sought to determine if thrombocytes are capable of activation in response to these 
agonists and how the thrombocyte response compares to that of platelets.  Due to a lack 
of species-specific activation markers for chicken thrombocytes, we performed [
3
H] 
serotonin (5-HT) secretion assays under non-stirring conditions as a means to directly 
compare the activation response of platelets and thrombocytes.  Chicken thrombocytes 
readily take up 5-HT from the plasma and release it upon activation, presumably through 
a degranulation mechanism similar to that of platelets
129,130
.  Thrombin stimulated [
3
H]5-
HT release in a concentration-dependent manner, although this stimulation was less 
potent  than that of human platelets (Fig. 3-2A).  The thrombin used in this assay was 
purified from a bovine source, and it is not clear if species-specific differences account 
for the lower sensitivity of chicken thrombocytes.  
 A gene encoding the platelet-specific collagen receptor GPVI was absent from 
our gene-expression analysis, and a BLAST search revealed no GPVI orthologs in the 
chicken genome.  However, it has been documented that chicken thrombocytes are 
capable of aggregating in response to collagen, although the relative strength of collagen 
as a thrombocyte agonist is unclear
130
.  Fibrillar equine type-I collagen induced [
3
H]5-HT 
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release from thrombocytes in a concentration-dependent manner, and this response was 
even more sensitive than that of human platelets (Fig. 3-2B).  However, consistent with 
the apparent lack of GPVI on chicken thrombocytes, thrombocytes were not activated by 
convulxin and only very weakly activated by collagen-related peptide (CRP), both of 
which are GPVI-specific agonists that induced potent activation of platelets (Fig. 3-2C).   
It has been unclear the extent to which ADP or thromboxane, both of which are 
well characterized platelet agonists, can activate avian thrombocytes.  ADP did not 
induce any [
3
H]5-HT release in either thrombocytes or platelets (Fig. 3-2C), consistent 
with data demonstrating a lack of ADP-induced secretion in platelets in the absence of 
aggregation, when assays are performed in non-stirring conditions
133
.  Thrombocyte 
activation was also determined by the ability of agonists to induce aggregation of 
thrombocytes in thrombocyte-rich blood plasma.  Collagen induced thrombocyte 
aggregation, whereas ADP and the thromboxane analog U-46619 at high pharmacologic 
concentrations induced only transient and weak thrombocyte aggregation (Fig. 3-2D).  5-
HT, which has been reported to induce duck thrombocyte aggregation, did not induce any 
aggregation response in chicken thrombocytes at high pharmacologic doses (Fig. 3-
2D)
127
.  Annexin V and human fibrinogen binding following stimulation of washed 
thrombocytes was analyzed by flow cytometry but could not produce a readout of 
thrombocyte stimulation (data not shown). 
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Collagen-induced signaling in the thrombocyte requires Src-kinases and Syk. 
Unlike most activating receptors on the platelet surface, which are G-protein coupled, 
GPVI is a member of the immunoglobulin (Ig) domain-containing superfamily and 
utilizes tyrosine kinase signaling through Src-family kinases (SFKs) and Syk kinase (see 
Fig. 1-2)
46
.  To determine if collagen-induced thrombocyte activation is also dependent 
on these tyrosine kinases, we measured the ability of the SFK inhibitor PP2 and the Syk-
inhibitor piceatannol to inhibit collagen-induced [
3
H] 5-HT release.  Both PP2 and 
piceatannol inhibited collagen-induced thrombocyte [
3
H] 5-HT release in a dose-
dependent fashion (Fig 3-3A and B) and were more selective for inhibiting collagen-
induced, but not thrombin-induced, secretion (Fig. 3-3C).  Interestingly, PP2 was 
observed to partially inhibit thrombin-induced [
3
H] 5-HT release in the thrombocyte, 
whereas it had no affect on thrombin activation of platelets (Fig. 3-3C).  
 
Thrombocytes do not form aggregates on a collagen surface under arterial shear 
conditions. 
The ability of platelets to adhere and form aggregates when exposed to collagen under 
high shear and the cellular and molecular mechanisms underlying this process have been 
thoroughly characterized (see Fig 1-3).  It is unknown whether thrombocytes, which 
would be subject to much greater shear forces proportional to the square of their 
diameter—9-25 times the forces on platelets—are capable of this function.  The fact that 
thrombocytes express the GPIb/V/IX complex and the high-affinity collagen receptor 
integrin #2 suggested that vWF-mediated rolling and integrin-mediated adhesion may be 
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conserved.  To test whether thrombocytes are capable of rolling, adhering, and 
aggregating on a collagen surface under high shear, we perfused chicken and human 
whole blood anticoagulated with the direct thrombin inhibitor PPACK over a chicken 
collagen surface.   Chicken type-I and III collagen was purified from chicken skin and the 
resultant collagen-coated slides had a more heterogeneous collagen distribution than 
slides coated with the commercially available Chronolog type-I collagen derived from 
equine tendon (Fig 3-4).  We used chicken collagen for the hemodynamic flow assays to 
avoid any possible species-specific effects of the collagen type on thrombocyte adhesion 
under flow. 
These flow assays reproduce a critical element of platelet-collagen interaction in 
vivo—the need to adhere firmly to immobilized collagen under hemodynamic shear—but 
isolate the function of collagen-induced platelet activation by excluding thrombin 
generation and endothelial cell contribution (see Fig. 1-3).  To allow for real-time 
fluorescent imaging of adherent cells, platelets and thrombocytes were labeled with the 
mouse mAb AP-2, which binds both human and chicken #2b$3
123
.  AP-2 blocks 
fibrinogen binding by up to 50% in human platelets when used at high concentrations but 
appears to have only a minor effect on thrombocyte-fibrinogen binding
129,134
.  AP-2 does 
not inhibit thrombocyte aggregation in response to thrombin
123,126
.  During flow of 
human blood over collagen, platelets rolled and firmly adhered, and after 5 min of 
perfusion, large 3-dimensional aggregates had formed on the collagen surface 
(Supplemental movie 3-1).  Perfusion of chicken whole blood revealed thrombocytes 
rolling and firmly adhering to the collagen surface, and membrane tethers could be 
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observed (Supplemental movie 3-2).  After 5 min of perfusion, a large number of 
thrombocytes had firmly adhered but covered a much smaller total collagen surface area 
compared to platelet coverage (Fig. 3-5).  Most profoundly, thrombocytes were not 
observed to form any aggregates on the collagen surface, whereas platelets formed large 
aggregates in a shear-dependent fashion, consistent with previous findings (Fig. 3-5B-
D)
40
. 
To determine if thrombocytes are capable of aggregate formation if given more 
time to set down adherent cells, chicken blood was perfused over collagen for 15 min.  
Remarkably, after 15 min, a monolayer composed of more thrombocytes than observed in 
5-min perfusion experiments had formed on the collagen surface, but virtually no 3-
dimensional aggregates had formed (Fig. 3-6).  The lack of 3-dimensional aggregate 
formation by thrombocytes was most evident in DAPI-stained images that detect each 
thrombocyte nucleus.  While thrombocytes might be closely approximated to one 
another, and in some cases were in direct contact with one another, there was no overlap 
of individual nuclei, suggesting that no cells were stacked on top of each other (Fig. 3-
6B).  Together, these results suggest that thrombocytes have a conserved mechanism to 
adhere to collagen under arterial shear, but unlike platelets, they do not cover a collagen 
surface as efficiently and do not form aggregates under hemodynamic flow conditions.   
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Thrombocytes are fully activated despite a lack of aggregate formation under 
hemodynamic flow. 
Platelet adhesion and aggregate formation under flow are associated with a flattening of 
the platelet shape and formation of filopodia and lamellipodia.  The spreading of fully 
activated platelets presumably facilitates aggregate formation by allowing for more 
efficient stacking of platelets on top of each other.  To determine if thrombocytes are 
fully activated and undergo a similar shape change during aggregate formation, we 
performed scanning electron microscopy of platelets and thrombocytes following a 5-min 
perfusion of whole blood over chicken collagen through the parallel plate flow chamber.  
High-power imaging confirmed that thrombocytes covered significantly less surface area 
compared to platelets and did not form 3-dimensional aggregates (Fig. 3-7A and B).  
Large, 3-dimesnsional aggregates were readily observed for platelets following whole 
blood perfusion under the same conditions (Fig. 3-7A and B).  Individual thrombocytes 
and platelets appeared fully activated, as evidenced by cell spreading, accompanied by 
filopodia and lamellipodia formation and cell vacuolization, which suggested 
thrombocyte degranulation (Fig. 3-7C).  Occasional cell-cell contacts between 
thrombocytes could be observed, presumably a result of membrane extensions and 
fibrinogen-mediated thrombocyte cross-linking (Fig. 3-7B and E).  In contrast, platelet 
cross-linking was extremely robust, resulting in large aggregates and creation of a platelet 
lattice (Fig. 3-7D).   
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Pharmacologic inhibition of integrin function or collagen signaling decreases 
thrombocyte adhesion to collagen under flow. 
Integrin activation is required to mediate firm adhesion to collagen under flow.  To assess 
the requirement for integrins to mediate adhesion of thrombocytes, we used EDTA to 
chelate cations required for integrin function.  EDTA inhibited thrombocyte and platelet 
adhesion to collagen, suggesting that collagen-induced activation of integrins under shear 
is a conserved process (Fig. 3-8A).   
Collagen-induced platelet activation through GPVI signaling is required for 
normal platelet adhesion to collagen under hemodynamic flow, and pharmacologic 
inhibition or genetic deletion of GPVI significantly reduces platelet adhesion under 
shear
40
.  To test whether collagen-induced thrombocyte activation is required for 
adhesion under shear, we used PP2 to inhibit collagen-mediated signaling.  Following 5-
min perfusion of whole blood pre-treated with PP2, both platelet and thrombocyte surface 
coverage of collagen was reduced to a similar degree (Fig. 3-8B and Supplemental 
movies 3-3 and 3-4).  Following PP2 treatment, both platelets and thrombocytes 
demonstrated an increased amount of rolling along the collagen surface, with delayed or 
absent firm adhesion to collagen (Supplemental movies 3-3 and 3-4).  These results 
suggest that for both platelets and thrombocytes, collagen-induced signaling under 
hemodynamic flow is required for cellular activation and efficient transition from a 
rolling state to a firmly adherent state. 
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Thrombocytes express fewer #2b$3 integrin receptors than do platelets and are not 
affected by #2b$3 inhibition during adhesion to collagen under flow. 
The observation that thrombocytes do not form aggregates under hemodynamic flow 
could be expected if thrombocytes were to express significantly lower levels of #2b$3 
integrin on the cell surface.  #2b$3 is the most abundant platelet surface receptor, 
expressed at a copy number of approximately 50-80,000 receptors per cell, and, as a 
result, is found at an extremely high density on the cell surface
135
.  To compare the levels 
of #2b$3 on the surface of human platelets to that on the surface of chicken thrombocytes, 
we compared staining with AP-2 mAb by flow cytometry.  Remarkably, the expression 
of #2b$3 on the platelet surface was significantly greater than that on the thrombocyte 
surface (MFI 653 on platelets compared to 322 on thrombocytes; P = 0.018) (Fig. 3-9A).  
Taking into account a conservative estimate of thrombocyte versus platelet size—
assuming a platelet diameter of 2 µm and a thrombocyte diameter of 6-7 µm—and 
assuming a spherical shape for both cells, a thrombocyte could be expected to have a 
surface area at least 9-12.25 times that of a platelet.  This difference in surface area would 
result in an 18.2-24.8 times greater density of #2b$3 on the platelet compared to the 
thrombocyte. 
To test the importance of #2b$3 in platelet and thrombocyte responses to collagen 
under hemodynamic flow, we pharmacologically inhibited #2b$3 with eptifibatide, a 
cyclic lys-gly-asp peptide that prevents #2b$3 binding to fibrinogen
136
.  Eptifibatide 
inhibited collagen-induced aggregation of thrombocytes (Fig. 3-9B).  After 5 min of 
perfusion of eptifibatide-treated whole blood, platelet surface coverage of collagen was 
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dramatically reduced at high shear forces of 1300 and 1150 s
-1
 yet was paradoxically 
increased at lower shear forces of 700-350 s
-1
 (Fig. 3-9Ci).  Eptifibatide treatment had no 
effect on thrombocyte adhesion to collagen under flow (Fig. 3-9Cii and Supplemental 
movie 3-6).  By blocking platelet aggregation, eptifibatide treatment resulted in 
deposition of single platelets only and the absence of platelet aggregates (Fig. 3-9D and 
Supplemental movie 3-5).  Pharmacological inhibition of #2b$3 on platelets resulted in a 
monolayer formation on the collagen surface analogous to normal thrombocyte adhesion 
following whole blood perfusion.  These results demonstrate that at high shear forces, 
platelets are dependent on aggregate formation to maximize surface coverage of collagen, 
whereas thrombocytes do not utilize aggregate formation to enhance surface coverage 
under hemodynamic flow.   
 
Platelets, but not thrombocytes, utilize ADP signaling to enhance adhesion and 
aggregate formation under hemodynamic flow. 
ADP, released from platelet dense granules during collagen activation under flow, 
promotes aggregate formation through autocrine and paracrine activation of P2Y 
receptors
137,138
.  While ADP treatment only resulted in weak and transient thrombocyte 
aggregation, this response was inhibited with the small molecule P2Y12 antagonist 
MesAMP (Fig. 3-10A).  Consistent with previously published findings, treatment of 
whole blood with MesAMP decreased platelet surface coverage and aggregate size 
following 5-min perfusion over collagen (Fig. 3-10B).  MesAMP did not decrease 
collagen surface coverage of thrombocytes under flow (Fig. 3-10C), consistent with 
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thrombocytes’ apparent lack of a robust ADP-mediated activation response.  These 
findings confirm that platelets utilize ADP signaling to enhance aggregate formation and 
surface coverage on collagen under flow, while they suggest that thrombocytes do not 
employ this positive-feedback mechanism to enhance shear-resistant adhesion.    
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Discussion 
The aggregation of platelets in response to collagen exposure following vascular injury 
allows for an efficient hemostatic response but also underlies the thrombotic 
pathophysiology of acute cardiovascular disease.  While anuclear platelets are 
responsible for cellular hemostasis in mammals and pathological thrombosis in humans, 
avian species circulate larger, nucleated thrombocytes, which are believed to serve a 
similar hemostatic function in birds.  The ability of thrombocytes to respond to collagen 
under hemodynamic flow has not been studied.  In this chapter, we demonstrate that 
while thrombocytes are capable of potent activation by collagen and firm adhesion to 
collagen under flow, thrombocytes, in contrast to platelets, do not form 3-dimensional 
aggregates under arterial flow conditions.  We provide evidence that this profound 
difference is due to the relatively low density of #2b$3 receptors on the thrombocyte 
surface and the lack of additional positive-feedback pathways that are required for 
maximal platelet surface coverage and aggregate formation.  
True anuclear platelets first appeared in early mammalian species.  The 
monotreme order, most closely related to primitive mammalian ancestors, consists of 
egg-laying mammals such as the duck-billed platypus and the echidna (spiny anteater).  
These species contain platelets of size and number similar to those found in mice and 
humans, although monotreme platelets may occasionally be larger than human or mouse 
platelets—up to 8 µm in diameter, similar in size to a thrombocyte7.  Marsupial species 
such as the opossum have platelet counts that are comparable to those of placental 
mammalian species.  One common misconception is the idea that placental birth was the 
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driving force behind the evolution of platelets.  The fact that monotremes, which are egg-
laying, and marsupials, which have a nonplacental pregnancy, both have platelets 
suggests that platelets did not evolve to facilitate placental birth. 
There is functional evidence that, as the major constituent of circulating cells after 
red blood cells, thrombocytes function as the hemostatic effector cells in non-mammalian 
vertebrates.  However, gene expression profiling of thrombocytes has not been performed 
to demonstrate that thrombocytes specifically upregulate platelet-specific genes 
associated with hemostatic function.  Our results show that, compared to lymphocytes, 
thrombocytes specifically express genes that have a distinct role in platelet function.  The 
fact that we limited our comparison of thrombocytes solely to lymphocytes does not 
eliminate the possibility that other blood cells such as granulocytes or monocytes could 
express hemostatic effector genes.  However, the fact that the K55-negative / AP-2 
negative population was relatively minor suggests that this cell population could not be 
contributing in large numbers to avian hemostasis.  Additionally, all adherent cells 
following flow on the collagen surface expressed #2b$3, as determined by AP-2 binding, 
suggesting that only thrombocytes are capable of this specialized shear-resistant 
behavior.  In summary, our results demonstrate that avian thrombocytes have a gene 
expression profile associated with hemostatic function. 
Results from parallel plate flow chamber experiments suggest that thrombocytes 
do not effectively form shear-resistant aggregates during flow over a collagen surface.  
This finding represents a fundamental difference from the behavior of platelets, which, 
even in the absence of thrombin generation, form large 3-dimensional aggregates on 
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collagen in a shear-dependent fashion.  What are the mechanisms that underlie this 
distinction?  In flowing blood, thrombocytes are subject to greater forces due to their 
larger cell size, proportional to the square of their diameter.  A thrombocyte of 7 µm in 
diameter could be subject to 12.25 times greater force compared to a platelet of 2 µm in 
diameter.  This increased force could negatively affect the ability of thrombocytes to 
build a growing aggregate in the setting of flowing blood.   
We attempted to address cellular and molecular mechanisms underlying this 
distinction in shear-resistant aggregate formation. Thrombocytes have a ~50% reduction 
in #2b$3 copy number on the cell surface, which results in an approximately 10-20-fold 
decrease in #2b$3 density, after taking the larger thrombocyte size into account.  The 
fibrinogen receptor, integrin #2b$3, is expressed at approximately 80,000 copy numbers 
on the platelet surface, resulting in a high density which accounts for 17% of the platelet 
membrane protein mass
139
.  Thrombocytes have sufficient #2b$3 density to mediate 
aggregation under stirring conditions, but greater densities, such as those found on 
platelets, may be required for aggregation under the more stringent conditions of 
hemodynamic flow at arterial shear rates.  This difference in integrin density between 
platelets and thrombocytes could underly the major distinction in aggregation behavior 
during flow over collagen.  It would be intriguing to overexpress #2b$3 in the chicken 
thrombocyte to see if increased integrin expression at densities similar to that of the 
platelet could allow for shear-resistant thrombocyte aggregation in whole blood flow.  
Although they are nucleated cells, thrombocytes are reported to be extremely difficult to 
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culture, posing an impediment to gene transfection and reconstitution of chicken blood 
with cultured thrombocytes
140
. 
Similar to platelets, thrombocytes appear fully activated, spread, and degranulated 
in response to collagen under flow, a prerequisite for platelet aggregation under these 
conditions.  The difference in cell size is the only major distinction between these two 
cell types as seen under high-power scanning electron microscopy analysis.  
Thrombocytes engage in robust cell spreading behavior, characterized by filopodia and 
lamellipodia formation, in a manner almost identical to platelets, suggesting evolutionary 
conservation of this response and an essential role for it in normal hemostatic function.  
It appears that thrombocytes may have a less extensive and/or less sensitive 
repertoire of agonists involved in potentiating thrombocyte activation.  While thrombin 
and collagen are both primary activators of thrombocytes and platelets, platelets utilize 
positive feedback via thromboxane and 5-HT signaling to maintain activation, and, most 
notably, they absolutely require ADP signaling to maximize adhesion to collagen under 
flow
137,138
.  Thrombocytes do not appear to have evolved a potent response to any of 
these agonists.  The possible existence of additional agonists, perhaps unique to 
thrombocytes and not platelets, cannot be ruled out.  Such agonists may serve to augment 
thrombocyte activation following thrombin or collagen stimulation.  However, in the 
absence of a high density of #2b$3 integrin and the potential for aggregation under high 
shear, robust autocrine and paracrine signaling during adhesion under flow may not have 
any additional effect.  It is possible that the adaptations that facilitate platelet aggregation 
under arterial blood flow conditions—small cell size, increased cell number, high #2b$3 
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density—co-evolved with positive-feedback pathways, such as a robust response to ADP, 
that potentiate platelet aggregation. 
The finding that chicken thrombocytes do not form aggregates over collagen 
following blood flow at arterial shear rates raises the question of what happens in birds 
following vascular injury.  It has been repeatedly demonstrated in mammalian injury 
model systems, most well characterized in the mouse, that vascular injury of a sufficient 
degree results in the formation of a platelet-mediated thrombus that occludes vessel flow.  
Our results from chicken thrombocyte studies raise several questions.  Is cell-mediated 
thrombosis strictly a platelet, and therefore, mammalian phenomenon?  Do birds form 
thrombi following vessel wall injury, and, if so, are there alternate mechanisms for this 
response other than thrombocyte aggregation, such as a robust coagulation response?  
Finally, is occlusive thrombus formation absolutely necessary to prevent hemorrhage 
following vascular injury, or is a cell monolayer sufficient for hemostasis in this setting?  
Thrombocytes appear capable of monolayer formation following adhesion to collagen 
under flow, and perhaps this response is suitable for hemostasis in avian species.  The 
mammalian adaptation of platelet-driven occlusive thrombus formation is most likely an 
adaptive response to significant vessel trauma designed to prevent catastrophic 
hemorrhage.  However, this response is also the driving force behind pathologic 
thrombosis that occurs in the setting of cardiovascular disease.  To answer these 
questions, comparative thrombosis experiments need to be designed in an avian model to 
determine the response of thrombocytes to vessel injury in vivo in the arterial system. 
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The hemodynamics and cardiovascular physiology of many non-mammalian 
species, such as reptiles and fish, is vastly different from that of mammals, making it 
difficult to predict the requirement for an efficient cellular hemostatic response.  Avian 
species, however, are warm-blooded, with a large cardiac output and higher blood 
pressures than mammalian species
122
.  In this sense, the presence of high-shear arterial 
flow reproduces a hemodynamic environment very similar to that of a mammalian 
system.  Some of the most recently characterized thrombocytes are those present in 
zebrafish and have been shown to activate in response to collagen and weakly activate in 
response to ADP—an activation profile similar to that of chicken thrombocytes
141-143
.  
Additionally, laser injury models of the caudal artery in 3- to 4-day post-fertilization 
zebrafish larvae demonstrate generation of thrombocyte aggregates, and, in some cases, 
occlusive thrombi
143,144
.  However, the arteries in these zebrafish models are small and 
have relatively low shear compared to large arteries found in avian or mammalian 
species.   Morpholino-injected knockdown of #2b only resulted in a 50% reduction in 
thrombus surface area in this model, whereas at arterial shear rates of 1300 s
-1
, 
eptifibatide-treated human platelets show a >90% reduction in aggregate surface area 
(Fig. 3-8D)
144
.  
Our finding that potent collagen-induced activation of hemostatic cells is 
conserved from platelets to thrombocytes indicates the importance of subendothelial 
collagen as a primary activator in hemostasis.  However, our studies suggest some 
fundamental differences between collagen-induced thrombocyte activation and GPVI-
induced platelet activation in response to collagen.  Thrombocytes are not activated by 
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the GPVI-specific ligands CRP, a collagen peptide mimetic, or convulxin, a snake venom 
toxin that binds a site of GPVI not required for collagen interaction.  CRP is a synthetic 
peptide consisting of 10 gly-pro-hydroxypro (GPO) repeats, cross-linked to create a 
quaternary structure
28
.  CRP is believed to specifically activate GPVI through 
coordination with certain basic residues exposed within an apical groove in the GPVI D1 
ectodomain and is believed to recapitulate the primary mechanism by which GPVI 
interacts with collagen
23,25,145,146
.  The fact that CRP does not activate chicken 
thrombocytes suggests that the primary means by which collagen interacts with its 
receptor(s) on thrombocytes is fundamentally different from that of the collagen-GPVI 
interaction.  It should be noted, however, that there are residues implied in collagen 
binding that have no effect on CRP binding, suggesting the GPVI binding sites for 
collagen and CRP are not entirely identical.   
The use of tyrosine kinase signaling for collagen-induced activation appears to be 
conserved from avian thrombocytes through mammalian platelets.  A thrombocyte-
specific Ig-receptor that couples to the immunotyrosine activating motif-containing FcR! 
subunit through a transmembrane arginine has been identified that binds chicken IgY
147
.  
It remains to be seen whether there is a single Ig-receptor or multiple receptors that are 
responsible for collagen-induced thrombocyte activation and if unique extra- or 
intracellular features of such receptors are conserved through mammalian GPVI. 
The lack of a chicken GPVI ortholog is consistent with our understanding that 
monotremes (egg-laying mammals), which diverged from therian (marsupial and 
placental) mammals approximately 150 million years ago and whose genome is 
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particularly well annotated, also do not contain a GPVI ortholog.  Furthermore, the 
leukocyte-receptor complex (LRC), the gene cluster that encodes mammalian GPVI and 
other immunoglobulin (Ig) superfamily members, has undergone dramatic rearrangement 
from avian to monotreme to placental mammals
114,148-150
.  Chicken and mammalian 
paired Ig-receptors share basic structural similarities and ITAM-coupling mechanisms, 
but no direct chicken orthologs exist for mammalian LRC genes
114,151
.  It will be 
informative to determine the array of thrombocyte-specific Ig receptors and their role in 
hemostatic function. 
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Materials and methods 
Antibodies and reagents 
Mouse AP-2 mAb was a generous gift from Thomas Kunicki
123
.  Mouse K55 mAb was a 
generous gift from Hyun Lillehoj
152
.  Convulxin, type-I fibrillar collagen derived from 
equine tendon, and ADP were obtained from previously described sources
153
. Collagen-
related peptide (CRP) was generous gift from Debra Newman.  Thrombin from bovine 
plasma (40-300 NIH units/mg protein) was purchased from Sigma-Aldrich (St. Louis, 
MO).  PP2 and piceatannol were purchased form Calbiochem (San Diego, CA).  
Eptifibatide was purchased from Merck (Whitehouse Station, NJ).  MesAMP was 
purchased from Axxora (San Diego, CA).  Alexa-Fluor 488 and 647 Monoclonal 
Antibody Labeling Kits and Alexa-Fluor 594-conjugated phalloidin were purchased from 
Molecular Probes (Carlsbad, CA).   
 
Blood collection and preparation 
Chicken studies 
Blood was collected from the wing vein of healthy female Rhode Island red pullet 
chickens, aged approximately 6 months, from a commercial source using a 19-gauge 
butterfly needle into 10-mL or 30-mL syringes anticoagulated with either 1:10 (v/v) 
93µm D-phenylalanyl-L-prolyl-L-arginine chloromethyl ketone (PPACK) or 1:6 (v/v) 
acid/citrate/dextrose (65 mM Na3citrate•2H2O, 70 mM citric acid•H2O, 100 mM 
dextrose, pH 4.4) or 1:9 (v/v) sodium citrate (130 mM Na3citrate•2H2O, pH 7.4).  Whole 
blood was diluted 1:1 in modified Tyrode’s buffer (137 mM NaCl, 20 mM HEPES, 2.7 
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mM KCL, 3.3 mM NaH2PO4, 5.6 mM glucose, 1 g/L BSA, pH 7.4) containing 1 mM 
MgCl2, and 12-mL aliquots were spun at 50 g for 5 min.  The thrombocyte-rich plasma 
layer was isolated by aspiration pipetting.  For preparation of washed thrombocytes, 1 
U/mL apyrase and 1 µM prostacyclin were added to thrombocyte-rich plasma, and 
samples were washed once in platelet wash buffer (10 mM HEPES, 1 mM EDTA, 150 
mM NaCl, pH 6.0) before resuspending in modified Tyrode’s buffer.  Cells were counted 
using a hemocytometer, and the larger, ovoid red blood cells were deliberately not 
counted. 
Human studies 
Blood was collected from 6 healthy donors using a 19-gauge butterfly needle into 10 mL 
or 30 mL syringes anticoagulated as described above.  Washed platelets were prepared 
are described for thrombocytes above.  
 
Chicken plasma cell transcriptional profiling 
Washed thrombocyte-rich plasma from 3 separate chicken blood collections was co-
stained with Alexa-Fluor 488-conjugated K55 mAb and Alexa-Fluor 647-conjugated AP-
2 mAb for 30 min, washed with phosphate-buffered saline, and resuspended in 
Dulbecco’s Modified Eagle Medium (Invitrogen, Carlsbad, CA) at 40 x 10
7
 cells per mL.  
2 x 10
6
 K55 positive, AP-2 negative cells (lymphocytes) and K55 negative, AP-2 positive 
cells (thrombocytes) were collected via cell sorting, and RNA was isolated using Trizol 
(Invitrogen) and RNAEasy Kit (Qiagen, Valencia, CA).  Thrombocyte and lymphocyte 
cDNA was produced using the Superscript® First Strand Synthesis Kit (Invitrogen). 
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Transcriptional profiling was performed by the University of Pennsylvania Microarray 
Facility using the GeneChip Chicken Genome Array (Affymetrix, Santa Clara, CA). 
 
[
3
H] 5-HT secretion assays 
Thrombocyte-rich plasma or platelet-rich plasma was incubated with [
3
H] 5-HT (2 !Ci 
[0.074 MBg]/mL) at 37 °C for 30 min.  Thrombocyte or platelet suspensions were 
washed and resuspended to final concentration of 2 x 10
7
 cells per mL or 2 x 10
8
 platelets 
per mL, respectively, in modified Tyrode’s buffer plus 1 µm imiprimine and 1 mM 
CaCl2. Cell aliquots of 500 mL were stimulated under non-stirring conditions at 37 °C for 
10 min.  In certain cases, inhibitors were added and cells were incubated at 37 °C for 10 
min prior to stimulation.  Reactions were stopped by addition of equal volume 2% 
paraformaldehyde and 0.1 mM EDTA followed by centrifugation at 10,000 g for 5 min.  
[3H] counts were measured from the supernatants of stimulated samples and 
unstimulated controls, which were used as background.  To determine total loading, [3H] 
counts were measured in an equal volume of loaded cells following lysis in an equal 
volume of fixing buffer plus 2% Triton X-100.  Percent serotonin release was represented 
as ([
3
H] sample – [
3
H] background) / ([
3
H] total – [
3
H] background) x 100.   Percent 
inhibition was represented as (% release with inhibitor) / (% release without inhibitor) x 
100. 
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Thrombocyte aggregation assays 
Thrombocyte-rich plasma collected from blood anticoagulated in sodium citrate was 
diluted to a concentration of 2 x 10
7
 cells per mL.  5 x 10
6
 cells were used for each 
stimulation.  Aggregation assays were performed as previously described
58
.   
 
Preparation of chicken collagen-coated slides 
An acid-soluble chicken collagen types-I and –III prep was prepared as described 
previously
154
.  Reconstitution of fibrilar chicken collagen was performed as previously 
indicated
155
.  Briefly, the collagen was dissolved in 0.5 M acetic acid at 1.5 mg/mL and 
dialyzed against 2 changes of 50 mM Tris HCl, pH 7.5 at 4 °C over 48 h.  After dialysis, 
the gelatinous white collagen precipitate was resuspended with a repeated aspiration 
through a 22-gauge needle and then sonicated with a steel probe sonicator (Branson 450 
Digital Sonifer®, Danbury, CT) on ice for 3 pulses of 5 sec at 10% amplitude with at 
least 15 sec between pulses.  Coating of microscope slides was performed as described 
previously 
40
.  Briefly, 300 µL of fribrillar chicken collagen was placed in a flexiperm 
well that was attached to an EtOH-washed  25 x 75 mm glass (Fisher, Pittsburgh, PA) or 
Permanox
TM
 (Nunc, Rochester, NY) microscope slide, for scanning electron microscopy 
assays, and incubated at 4 °C overnight.  Slides were then washed 2 times with PBS and 
blocked with 1% denatured BSA for at least 1 h at room temperature prior to use. 
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Whole blood flow assays 
The tapered-wall parallel plate flow chamber was assembled as previously described
40,156
.  
The assembled chamber was then placed on the stage of an inverted microscope (Nikon 
Eclipse TE2000-U, Melville, NY).  Blood collected in PPACK was warmed at 37 °C for 
10 min, along with inhibitors, and 2.5 µg/mL fluorescently labeled Alexa-Fluor 488-
conjugated AP-2 mAb was added, which binds both human and chicken #2b$3 to label 
platelets or thrombocytes
123
.  Whole blood was perfused over the collagen-coated glass 
slide at a flow rate of 0.428 mL/min using a syringe pump (Model ‘11’ Plus; Harvard 
Apparatus) for 5 min.  After whole blood perfusion, chambers were rinsed with modified 
Tyrode’s buffer at the same flow rate for 5 min prior to static image collection. 
 
Whole blood flow image capture and analysis 
During whole blood flow, platelet or thrombocyte adhesion was monitored continuously 
by epifluorescence microscopy.  Images were captured using a CCD camera (C9300-201 
Hamamatsu, Bridgewater, NJ) mounted on an inverted microscope with a 300 W Xenon 
lamp (Perkin Elmer Optoelectronics, Freemont, CA) through a Lambda DG-4 high-speed 
filter changer (Sutter Instruments, Novato, CA) used at 470 nm Ex / 525 nm Em.  For 
real-time fluorescent microscopy during blood flow, images were captured continuously 
with a 300 ms exposure time at an interval of 100 ms using Slidebook software 
(Intelligent Imaging Innovations) as previously described
153
.  Static image collection was 
obtained using epifluorescence microscopy at different axial positions along the flow 
chamber that correspond to a given shear rate.  Platelet or thrombocyte percent surface 
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coverage and average aggregate size were quantified using ImageG software (National 
Institutes of Health).  Both results were reported as the mean plus or minus standard error 
of the mean (SEM).   
 
Fluorescent microscopy of collagen slides following whole blood flow 
Slides were removed from the flow chamber and fixed in 1% paraformaldehyde for 5 min 
and washed 3 times in PBS.  Slides were then permeabilized in 0.02% Triton X-100 in 
PBS with BSA 1 mg/mL for 5 min followed by 3 washes in PBS.  Filamentous actin was 
stained with Alexa-Fluor 594-conjugated phalloidin (25 µL/mL) for 45 min at room 
temperature.  Slides were imaged with fluorescent microscopy as previously described
99
. 
 
Scanning electron microscopy of collagen slides following whole blood flow 
Permanox™ (Thermo Fisher Scientific, Rochester, NY) slides were coated with chicken 
collagen as described for glass slides.  Permanox was used to facilitate slide cutting for 
microscopy preparation.  Following whole blood perfusion, slides were removed from the 
flow chamber, washed 3 times in PBS, and fixed in 2% glutaraldehyde until microscopy 
analysis.  Slide sections were analyzed on a Philips XL20 scanning electron microscope. 
 
Flow cytometric analysis 
Washed platelets or thrombocytes were diluted to a concentration of 2.5 x 10
7
 platelets 
per mL or 2 x 10
7
 cells per mL, respectively, and 2.5 x 10
6
 platelets or 2.5 x 10
6
 
thrombocytes were stained with Alexa-Fluor 488-conjugated AP-2 mAb at room 
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temperature for 1 h and analyzed by flow cytometry.  Mean fluorescent intensity of AP-
2-positive cells was quantified for platelets and thrombocytes.   
 
Thrombocyte spreading assay 
Lab-Tek II chamber slides (Thermo Fischer Scientific, Rochester, NY) were coated with 
type I fibrillar collagen (Chronolog) at 30 µg/mL in 50 µM acetic acid for 16 h at 4 °C, 
washed 3 times with PBS, and blocked with BSA 1 mg/mL in PBS for 30 min at room 
temperature.  Thrombocyte-rich plasma was diluted to 2 x 10
7
 cells per mL in modified 
Tyrode’s buffer containing 1 mM MgCl2 and 1 mM CaCl2, and 500 µL of cells were 
incubated on the collagen-coated chambers for 45 min at 37°C.  Fixation, permeablizing, 
and staining were performed as previously reported
153
. 
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Figure 3-1.  Analysis of chicken plasma preps by flow cytometry.  
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Figure 3-1.  Analysis of chicken plasma preps by flow cytometry.  A. Washed chicken 
thrombocyte-rich plasma was stained with Alexa-Fluor 488-conjugated AP-2 mAb and 
analyzed by flow cytometry.  Thrombocytes could be detected at a distinct forward and 
side scatter from leukocytes (compare gate 1 to gate 2) and were readily identified by 
expression of the thrombocyte-specific marker #2b$3 (AP-2-positive cells).   
B. Thrombocyte-rich plasma cells were sorted for transcriptional profiling based on 
positive and negative selection markers using the lymphocyte-specific mAb K55, which 
excludes thrombocytes, and the thrombocyte-specific mAb AP-2.  Gate 1 was specific for 
lymphocytes while gate 2 was specific for thrombocytes. 
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Table 3-I.  Detection of platelet-specific gene expression in thrombocytes by 
transcriptional profiling.  
 
 Gene   Ratio (T/L)  Fold Change    P value 
 
 
 
 
 
 
 
 
 
 
Table 3-I.  Detection of platelet-specific gene expression in thrombocytes by 
transcriptional profiling.   Thrombocytes and lymphocytes were sorted by positive and 
negative selection for cell-specific markers, and gene expression analysis was performed 
using the Affymetrix chicken gene chip.  The gene expression ratio of thrombocytes to 
lymphocytes (T/L), fold change, and P values for genes of known platelet specificity 
present in the chicken chip are shown.   
MPL 422.0 821.2 3.5E-05 
GP9 892.4 6.7 3.8E-04 
ITGB3 612.8 597.6 5.3E-05 
ITGB1 2.2 1.07 0.002 
ITGA6 5.2 1.02 0.004 
ITGA2 215  1.3E-06 
ITGAV 24.3 9.5 3.1E-04 
PAR1 26.3 1.36 0.001 
PAR4 7.0 1.005 0.007 
P2RX1 823.7 38.2 2.0E-04 
P2RY1 15.0 29.0 2.2E-04 
HTR2A 467.1 209.4 1.0E-04 
CD36 1027.5 4.03 5.0E-04 
TBXAS1 74.8 42.5 2.0E-04 
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Figure 3-2.  Activation of chicken thrombocytes by collagen and thrombin.   
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Figure 3-2 (cont’d).  Activation of chicken thrombocytes by collagen and thrombin.   
 
D 
          
 
         
 121 
Figure 3-2.  Activation of chicken thrombocytes by collagen and thrombin.  5-HT 
release from platelets or thrombocytes was measured following loading with [
3
H] 5-HT.  
Cells were stimulated with increasing doses of bovine thrombin (A) or equine type-I 
collagen (B) or various agonists (C).  In panel C, thrombin, collagen, and ADP were used 
at concentrations of 1 U/mL, 3.0 µg/mL, and 10 µM, respectively.  D. Aggregation of 
chicken thrombocytes in response to various agonists.  Thrombocyte-rich chicken plasma 
was stimulated with indicated agonists, and aggregation was measured by percent light 
transmittance in a luri-aggregometer. 
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Figure 3-3.  PP2 and piceatannol inhibit collagen-induced 5-HT secretion in 
thrombocytes in a dose-dependent manner.  
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Figure 3-3.  PP2 and piceatannol inhibit collagen-induced 5-HT secretion in 
thrombocytes in a dose-dependent manner.  
5-HT release from platelets or thrombocytes was measured following loading with [
3
H]-
5-HT.  Chicken thrombocytes were stimulated with either thrombin (1 U/mL) or collagen 
(3 µg/mL) in the presence of increasing doses of PP2 (A) or piceatannol (B).  C. PP2 (3 
µM ) and piceatannol (30 µM) were used to inhibit 1 U/mL thrombin- or 3.0 µg/mL 
collagen-induced 5-HT release in either human platelets or chicken thrombocytes.  In all 
panels, shown is the mean ± SD; n = 3 experiments per condition. 
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Figure 3-4.  Chicken collagen type-I and –III coated on glass slides.   
 
 
 
Figure 3-4.  Chicken collagen type-I and –III coated on glass slides.  Chicken collagen 
type-I and –III was purified from chicken skin and dialyzed against 0.05 M Tris-HCl pH 
7.5 to create a fibrillar peptide.  A. Chicken collagen was coated on glass slides overnight 
at 4 ºC.  B. Glass slides coated with Chronolog type-I equine collagen are shown for 
comparison.   
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Figure 3-5.  Thrombocytes cover less surface area and fail to form aggregates 
during adhesion to collagen under whole blood flow.  
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Figure 3-5 (cont’d).  Thrombocytes cover less surface area and fail to form 
aggregates during adhesion to collagen under whole blood flow.  
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Figure 3-5.  Thrombocytes cover less surface area and fail to form aggregates 
during adhesion to collagen under whole blood flow.  PPACK-anticoagulated human 
or chicken whole blood was labeled with AP-2 mAb and perfused through a tapered-wall 
parallel plate flow chamber for 5 min over a chicken collagen-coated glass slide.   
A. Time traces of percent surface coverage of collagen surface by platelets or 
thrombocytes.  Shown is mean ± SD; n = 7-10 for each condition.  B. Representative 
fluorescent images captured at areas corresponding to shear rates of 1300, 1100, 700, and 
400 s
-1
 after 5 min perfusion of whole blood.  C.  Representative images of thrombocyte 
or platelet adhesion to collagen following whole blood flow for 5 min at 1300 s
-1
.  Slides 
were fixed, permeabilized, and stained with Alex-Fluor 594-conjugated phalloidin to 
detect actin filaments.  Nuclear staining of thrombocytes with DAPI is also shown.   
D. Percent collagen surface area coverage (i) and mean aggregate area (ii) of human 
platelets or chicken thrombocytes following perfusion of whole blood for 5 min was 
determined by analysis of fluorescent images.  Shown are the mean ± SEM; n = 7-10 
experiments for each condition.  
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Figure 3-6.  Chicken thrombocytes do not form aggregates after extended flow of 
whole blood.    
 
 
Figure 3-6.  Chicken thrombocytes do not form aggregates after extended flow of 
whole blood.   A. Representative fluorescent images captured at areas corresponding to 
shear rates of 1300, 1100, 700, and 400 s
-1
 after 15 min perfusion of chicken whole 
blood.  B. Representative images of thrombocyte adhesion to collagen following whole 
blood flow for 15 min at 1300 s
-1
.  Slides were fixed, permeabilized, and stained with 
phalloidin and DAPI.  Note that each adherent thrombocyte can be distinctly visualized 
by DAPI staining, demonstrating an absence of 3-dimensional aggregation. 
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Figure 3-7.  Scanning electron microscopy of platelets and thrombocytes following 
adhesion to collagen under whole blood flow.  
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Figure 3-7.  Scanning electron microscopy of platelets and thrombocytes following 
adhesion to collagen under whole blood flow.  PPACK-anticoagulated human or 
chicken whole blood was perfused through a tapered-wall parallel plate flow chamber for 
5 min over a chicken collagen-coated slide.  Images were obtained by scanning electron 
microscopy at regions corresponding to a shear rate of approximately 1300 s
-1
.  Platelets 
and thrombocytes were imaged at magnifications of 650 X (A), 2000X (B), and 8000 X 
(C).  D. The inside of a platelet aggregate imaged at 10,000 X.  E. Adherent 
thrombocytes forming membrane contacts at 3500 X. 
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Figure 3-8.  Thrombocyte adhesion to collagen under flow is sensitive to Src-family 
kinase inhibition. 
  
 
Figure 3-8.  Thrombocyte adhesion to collagen under flow is sensitive to Src-family 
kinase inhibition.  A. Percent collagen surface area coverage of platelets (i) or 
thrombocytes (ii) following perfusion of 5 mM EDTA-treated whole blood for 5 min was 
determined by analysis of fluorescent images.  B. Percent collagen surface area coverage 
of human platelets (i) or chicken thrombocytes (ii) following perfusion of 10 µM PP2-
treated whole blood for 5 min.  Shown are the mean ± SEM; n = 4 experiments for each 
condition. 
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Figure 3-9.  Thrombocytes express fewer #2b$3 integrin receptors than do platelets 
and are not affected by #2b$3 inhibition during adhesion to collagen under flow.  
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Figure 3-9.  Thrombocytes express fewer #2b$3 integrin receptors than do platelets 
and are not affected by #2b$3 inhibition during adhesion to collagen under flow.   
A. Levels of #2b$3 integrin expression on washed human platelets and washed chicken 
thrombocyte-rich plasma were determined by staining with AP-2 mAb and analyzed by 
flow cytometry.  i. Representative staining of human platelets and chicken thrombocytes 
for the #2b$3 integrin, as determined by AP-2 mAb binding.  Gates denote regions 
analyzed, and only AP-2 positive cells were analyzed for mean fluorescence intensity 
(MFI).  ii. The histogram depicts MFI of AP-2 binding ± SD.   
B. Eptifibatide inhibits chicken thrombocytes aggregation.  Thrombocytes were 
stimulated with 1 µg/mL collagen in the presence or absence of 10 µM eptifibatide, and 
aggregation was measured by percent light transmittance in a luri-aggregometer.   
C. Percent collagen surface area coverage of human platelets (i) or chicken thrombocytes 
(ii) following perfusion of 10 µM eptifibatide-treated whole blood for 5 min was 
determined by analysis of fluorescent images.  D. Mean platelet aggregate area following 
perfusion of 10 µM eptifibatide-treated whole blood for 5 min.  For panels C and D, 
shown are the mean ± SEM; n = 4 experiments for each condition. 
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Figure 3-10.  The effect of P2Y12 inhibition on platelet and thrombocyte adhesion to 
collagen under flow. 
 
 
 
Figure 3-10.  The effect of P2Y12 inhibition on platelet and thrombocyte adhesion to 
collagen under flow.  A. MesAMP inhibits thrombocyte aggregation.  Thrombocytes 
were stimulated with 100 µM in the presence or absence of 75 µM MesAMP, and 
aggregation was measured by percent light transmittance in a luri-aggregometer.  Percent 
collagen surface area coverage of human platelets (B) or chicken thrombocytes (C) 
following perfusion of 75 µM MesAMP-treated whole blood for 5 min was determined 
by analysis of fluorescent images.  Shown are the mean ± SEM; n = 4 experiments for 
each condition.   
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Supplemental movie legends 
For all movies, PPACK-anticoagulated human or chicken whole blood was labeled with 
AP-2 mAb and perfused through a tapered-wall parallel plate flow chamber for 5 min 
over a chicken collagen-coated glass slide.  Each movie depicts cell adhesion at a shear 
rate of 1200 s
-1
. 
Supplemental movie 3-1.  Adhesion of human platelets following perfusion of whole 
blood over chicken collagen.  
 
Supplemental movie 3-2.  Adhesion of chicken thrombocytes following perfusion of 
whole blood over chicken collagen.  
 
Supplemental movie 3-3.  Adhesion of human platelets following treatment with 30 
µM PP2 and perfusion of whole blood over chicken collagen.  
 
Supplemental movie 3-4.  Adhesion of chicken thrombocytes following treatment 
with 30 µM PP2 and perfusion of whole blood over chicken collagen.  
 
Supplemental movie 3-5.  Adhesion of human platelets following treatment with 75 
µM eptifibatide and perfusion of whole blood over chicken collagen.  
 
Supplemental movie 3-6.  Adhesion of chicken thrombocytes following treatment 
with 75 µM eptifibatide and perfusion of whole blood over chicken collagen.  
 136 
Chapter 4—Conclusions and future directions 
 
Summary 
Collagen-induced activation of platelets is believed to be a primary step in platelet 
function during physiologic hemostasis and pathologic thrombosis.  The immune-type 
receptor GPVI is a platelet-specific receptor required for collagen-induced activation.  In 
Chapter 2, we demonstrate that the GPVI receptor contains a proline-rich domain, unique 
to GPVI compared to other homologous receptors, that constitutively binds and directly 
activates the Src-family kinase Lyn.  The interaction of GPVI and Lyn via the proline-
rich domain accelerates GPVI signaling kinetics and is required for efficient platelet 
adhesion to collagen under flow.  In Chapter 3, we characterize the collagen response of 
the chicken thrombocyte, which expresses platelet-specific receptor orthologs but does 
not contain GPVI.  Thrombocytes are capable of activating in response to collagen, using 
a signaling pathway analogous to that of GPVI, and they adhere to collagen under high 
shear.  However, thrombocytes express a significantly lower level of #2b$3 integrin than 
do platelets, and they do not form 3-dimensional aggregates under flow conditions.  Our 
studies demonstrate fundamental conservation of responses to collagen by hemostatic 
cells but suggest that platelets have adapted additional mechanisms to promote 
aggregation under high shear conditions.  Moreover, our findings raise new questions 
about GPVI signaling and thrombocyte function in hemostasis.   
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Use of immune-type receptor signaling to activate hemostatic cells in response to 
collagen 
GPVI is well characterized as a platelet-activating receptor that uses an immune tyrosine 
kinase pathway to activate platelets.  Most other activating receptors on platelets are G 
protein-coupled and use a fundamentally different signaling pathway.  A potential, albeit 
simplified, explanation for why an immune signaling response to collagen may be 
advantageous compared to a G protein-coupled response is the fact that signaling via 
receptor clustering (immune-type receptors, driven by avidity) rather than conformational 
change (G protein-coupled receptors, driven by receptor-ligand affinity) allows for a 
graded and sustained signaling response.  As the major component of the subendothelial 
matrix, collagen, exposed following vessel injury, may be the first ligand encountered by 
the platelet.  Use of an immune receptor signaling pathway allows platelet activation to 
be modulated depending on the degree of collagen exposure.  The response of platelets to 
collagen may be excessive in pathological situations where the balance shifts from 
hemostatic platelet activation to pathological thrombosis.  Nevertheless, our findings in 
Chapter 2 show that the classical mechanism of immune receptor signaling employed by 
B-cells and T-cells has been modified by platelet GPVI to suit the unique context of 
collagen-induced activation under hemodynamic flow.   
The fact that GPVI contains a proline-rich domain that constitutively binds and 
directly activates Lyn means that the receptor is primed for rapid activation following 
ligand binding.  This molecular priming allows GPVI to function more effectively under 
arterial shear, where the platelet only has seconds to activate and firmly adhere.  While 
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this adaption of GPVI increases platelet responses to collagen under flow, it is not 
absolutely essential for this response.  Proline-rich domain-deleted GPVI platelets still 
adhere to collagen more effectively that GPVI-deficient platelets.  It is unknown whether 
the collagen receptor(s) on thrombocytes employ a proline-rich domain to accelerate 
signal transduction.  It could be difficult and misleading to calculate a relative adhesive 
efficiency for platelets compared to thrombocytes, but thrombocytes do not seem to be 
defective in transitioning from the rolling phase to the firmly adherent phase.  
Thrombocytes, like platelets, are clearly engineered for shear resistant adhesion to 
collagen under flow, and this behavior is equally sensitive to Src-family kinase inhibition 
in both cell types.  Therefore, the initial response to collagen, in both signal transduction 
and adhesion under flow, appears conserved between platelets and thrombocytes.  The 
fundamental difference between platelets and thrombocytes seems to lie outside of their 
relative responses to collagen and relates more significantly to their basic mechanisms 
promoting aggregate formation under high shear.  
 
Future directions for GPVI and thrombocyte research 
Our observations provide insight into the molecular function of GPVI in platelet biology 
and characterize the response of a more primitive hemostatic cell—the thrombocyte—
during adhesion to collagen under whole blood flow.  Our results uncover new questions 
that require future investigation. 
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Is GPVI / FcR! embedded in the cell membrane to prevent constitutive signaling from 
bound and activated Lyn kinase? 
Our findings in Chapter 2 suggest that GPVI keeps Lyn constitutively bound and held in 
an active state. We propose that, in order to prevent the undesirable effects of constitutive 
signaling through the GPVI / FcR! complex, the GPVI cytoplasmic tail and/or the FcR! 
chain is embedded in the platelet membrane, keeping the GPVI-bound Lyn and the FcR! 
ITAM at a suitable distance from one another to prevent activation prior to receptor 
ligation.  Xu et al. have demonstrated that the membrane-proximal basic residues on the 
CD3& chain of the T-cell receptor mediate binding to the cell membrane and keep the 
CD3& ITAM embedded in the lipid bilayer112.  Both GPVI and FcR! have an enrichment 
of positively charged amino acids on the proximal end of their cytoplasmic tails.  We 
believe GPVI / FcR! is an excellent model to test the functional requirements of these 
membrane-proximal basic residues in preventing constitutive GPVI signaling.  GPVI is 
an extreme example of an immune-type receptor that exists in a tightly coupled off-on 
state due to its identity as a hemostatic receptor primed to mediate rapid cellular 
activation following receptor ligation.   
Future studies aimed at determining whether the GPVI cytoplasmic tail and/or the 
FcR! chain are embedded in the membrane should be performed using a fluorescence 
resonance energy transfer (FRET) approach in lipid micelles, similar to that employed by 
Xu et al.  Membrane proximal basic residues in GPVI and FcR! can be mutated to 
determine if they are required to prevent constitutive signaling through GPVI in the 
absence of receptor ligation.  Use of retroviral complementation to express membrane 
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proximal mutants in GPVI-deficient bone marrow will be a useful strategy to determine 
the importance of these residues in GPVI surface expression and signaling in the platelet.  
 
What are the selective roles of Lyn and Fyn kinase in the initial events of GPVI 
signaling? 
Our findings in Chapter 2 are consistent with a model in which Lyn kinase is 
constitutively bound to GPVI and held in an activated state, primed to mediate immediate 
signaling following receptor ligation.  However, Fyn co-immunoprecipitates with the 
GPVI / FcR! signaling complex following receptor stimulation, and absence of Fyn 
confers a decrease in GPVI-induced platelet activation (see Chapter 2)
47
.  Our studies 
support a model in which Lyn drives initial GPVI signaling, whereas Fyn is responsible 
for sustained GPVI signaling required for potentiating GPVI-induced platelet activation.  
What are the mechanisms that underlie this division of labor for the Src-kinases Fyn and 
Lyn in GPVI signaling?  Our studies using a phage display suggest that Fyn does not 
have a high affinity for the GPVI proline-rich domain.  However, our biochemical studies 
and those of others have demonstrated that both Lyn and Fyn can associate with the 
GPVI proline-rich domain or perhaps with other members of the GPVI signaling complex 
(see Chapter 2)
95
.   
Specific investigation should focus on the relative affinities of Lyn and Fyn for 
GPVI and determining whether Fyn and Lyn associate with other members of the GPVI 
signaling complex, such as Syk, Slp-76, LAT, or PLC!2.  We predict that association of 
Fyn with GPVI or other signaling effectors may be facilitated through ligand-induced 
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GPVI clustering, and this mechanism should be investigated more thoroughly.  At an 
organism level, genetic experiments in collagen-dependent injury models using Fyn- and 
Lyn-deficient animals can determine if Lyn is selectively required for initial thrombus 
formation and Fyn is required for thrombus stability.  Such studies would refine our 
knowledge of downstream signaling events following GPVI stimulation by determining 
distinct roles for Fyn and Lyn in collagen-induced thrombus formation.   
 
What is the receptor responsible for activating thrombocytes in response to collagen? 
The fact that GPVI is a low-affinity receptor for collagen requires that alternative ligands 
other than native collagen had to be used to molecularly identify this platelet collagen 
receptor.  The identification of GPVI was aided by the fact that patient autoantibodies 
against GPVI and the snake venom toxin convulxin could serve as high-affinity ligands 
for use in biochemical assays
157,158
.  Identification of the thrombocyte collagen receptor is 
of interest because its lack of binding convulxin and CRP suggests it is structurally 
different from GPVI and may interact with collagen differently.  Our findings in Chapter 
3 suggest that the chicken thrombocyte collagen receptor uses an immunotyrosine kinase 
pathway dependent on Syk and Src-family kinases analogous to that of GPVI.  Methods 
to isolate the thrombocyte collagen receptor could employ a Syk tandem SH2 domain 
GST fusion protein to pull down the receptor-ITAM adaptor complex for protein 
analysis.  Identification of this receptor would provide further insight into the adaptation 
of immune receptors for collagen binding and signal transduction in hemostatic cells.  
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How is GPVI function conserved among mammalian species? 
The observation that chicken thrombocytes are activated by fibrillar collagen implies that 
collagen-induced activation of hemostatic cells has been conserved throughout evolution.  
It is intriguing that collagen signaling in both thrombocytes and platelets is sensitive to 
inhibition of Src-family kinases and Syk.  This finding suggests that the use of immune 
receptor signaling pathways to activate hemostatic cells in response to collagen has also 
been conserved—perhaps because the nature of immune receptor signaling allows for a 
graded response that is desirable for collagen-induced hemostatic activation.  It is 
impossible to know if mammalian GPVI evolved from collagen-sensing immune 
receptors found in more primitive species.   However, the fact that GPVI is not detectable 
in the platypus genome suggests that GPVI evolved after true non-nucleated platelets 
came be to utilized as dedicated hemostatic cells.  If this is correct, then a lack of 
response to GPVI-agonists should be observed in platelets from monotreme species but 
not in platelets from marsupials, the species most evolutionarily distant from placental 
mammals that have a GPVI ortholog. 
 To test whether monotreme or marsupial platelets respond to GPVI agonists, we 
obtained platelet samples from an echidna (spiny anteater), a monotreme, and a striped 
opossum (a marsupial).  While we would expect collagen-induced activation to be 
conserved in all these species, as they are conserved in more primitive thrombocytes, the 
ability to respond to GPVI-specific agonists like CRP is of interest because the echidna 
represents a “missing link”—a species that has platelets but does not express GPVI.  
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We have performed one set of preliminary experiments, and the results are 
somewhat consistent with gene ontology data suggesting that monotremes lack GPVI, 
while marsupials possess GPVI.  Platelets from the echidna did not activate in response 
to convulxin, as demonstrated by a lack of spreading on a convulxin-coated surface and a 
lack of fibrinogen binding in response to convulxin (Fig. 4-1).  In comparison, platelets 
from the opossum, a marsupial, spread on convulxin and bound fibrinogen in response to 
convulxin stimulation (Fig. 4-1).  These data support results from genetic database 
searches that indicate the presence of a GPVI ortholog in marsupial, but not monotreme, 
species.  Importantly, echidna, opossum, and mouse platelets all bind fibrinogen in 
response to ADP stimulation, suggesting that robust ADP-induced platelet activation is 
conserved and distinguishes platelet responses from those of thrombocytes.  To date, it is 
unknown if thrombocytes are direct ancestors of mammalian platelets or if platelets 
evolved separately.  Echidna platelets did not readily adhere to CRP, but those that did 
demonstrated spreading (Fig. 4-1A).  The significance of this finding is unknown, but it 
is possible that there are subset populations among echidna platelets that may express 
receptors capable of interacting with CRP (Fig. 4-1B).  
Interestingly, opossum platelets were not strongly activated by CRP, evidenced by 
only weak fibrinogen binding and a lack of robust spreading response (Fig. 4-1).  This 
finding is difficult to reconcile with the identity of a true GPVI ortholog in the opossum, 
but it should be mentioned that the GPVI ectodomain region responsible for collagen 
interaction is only partially conserved from opossum to mouse to human (Fig 4-2).  Key 
residues that have been implied in collagen and/or CRP binding are not present in 
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opossum GPVI, and the 11 amino acid deletion between GPVI and Fc#RI that creates a 
collagen-binding apical groove in GPVI is only a 5 amino-acid deletion in opossum 
GPVI (Fig 4-2).  Additionally, opossum GPVI contains an extracellular stalk that is 31 
residues longer than that of human or mouse GPVI and is poorly conserved.  It is difficult 
to speculate on the significance of these differences, but it is possible that the 
fundamental nature of the GPVI-collagen interaction has not been highly conserved in 
mammalian species and has undergone continued evolution.  This lack of conservation is 
in contrast with the highly conserved cytoplasmic proline-rich domain studied in Chapter 
2 and supports the characterization of GPVI as a collagen sensor selected through 
evolution for its signal transduction rather than its collagen binding properties.  However, 
it is known that human GPVI has a higher affinity for CRP than does mouse GPVI
159
.  
The fact that opossum GPVI has little or no ability to be activated by CRP suggests that 
improving affinity for the GPO repeats constituting a fraction of the native collagen 
peptide may have increased the sensitivity of GPVI as a hemostatic collagen receptor. 
 
If thrombocytes do not form aggregates on collagen under arterial flow conditions, how 
does cellular hemostasis function in avian species? 
The use of flow chambers to model platelet adhesion to collagen under arterial shear 
conditions reproduces a fundamental aspect of platelet biology—the formation of a 
platelet-driven thrombus in both in vivo injury models in the mouse arterial system and in 
human coronary thrombosis following atherosclerotic plaque rupture.  The fact that 
chicken thrombocytes do not form aggregates in the flow chamber system, whereas 
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platelets do, raises the question of how thrombocytes respond in vivo following arterial 
injury.  Do injuries to bird arteries equivalent to those used in mouse injury models result 
in an occlusive thrombus?  Are thrombocytes capable of forming aggregates in high-
pressure vessels following exposure of ECM components?  Alternatively, are there 
additional factors present in vivo that are not reproduced in flow chamber models that 
allow for shear-resistant aggregate formation?  We hypothesize that cellular thrombus 
formation under arterial shear in vivo is a platelet-specific, and therefore mammalian-
specific, phenomenon. 
 In order to answer these questions, an arterial injury model needs to be developed 
for avian species.  We are working on establishing a model where we can isolate a bird 
carotid artery that is equivalent in size to that of a mouse carotid and use FeCl3 to injure 
endothelial cells and expose subendothelial collagen
69
.  This injury model reproducibly 
generates a platelet-driven occlusive thrombus in wild-type mice.  A doppler flow probe 
will be used to determine the presence of, and time to, occlusion following FeCl3 injury.  
We will also take vessel specimens for histology following injury to determine the 
thrombocyte response following application of FeCl3.  Identical experiments on wild-type 
mouse carotids will be performed as controls.  We predict three possible results, all of 
which would be informative:  (1) the avian carotid artery does not occlude following 
injury, consistent with the ability of thrombocytes to form a monolayer on collagen under 
arterial flow but not form 3-dimensional aggregates; (2) the avian carotid does occlude, 
but utilizes a more robust coagulation response to form a thrombocyte-poor thrombus; (3) 
the avian carotid occludes via a thrombocyte-rich thrombus, suggesting that mechanisms 
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not represented in the flow chamber, such as the contribution of thrombin or other 
agonists, are required for thrombocyte-mediated thrombosis. 
 These studies will determine if the ability of hemostatic cells to form occlusive 
thrombi in vivo is unique to mammals.  The results of this work can provide insight into 
the evolutionary adaptations of the response to traumatic injury.  These studies will also 
address whether, by acquiring the ability for shear-resistant aggregation, the presence of 
platelets, rather than thrombocytes, fundamentally predisposes humans to cardiovascular 
morbidity and mortality.    
 
Concluding remarks:  The evolution of platelet responses to collagen under 
conditions of hemodynamic flow 
Fibrillar collagen is the major component of the subendothelial ECM and serves as both 
an adhesive surface and activating stimulus for platelets in the circulation.  In multiple 
ways, platelets are uniquely engineered to arrest their flow, activate, and aggregate under 
the high shear conditions of the arterial system.  Essential elements that mediate the 
function of platelets in hemostasis and pathological thrombosis include:  the small size of 
the platelet; high platelet numbers in blood; robust signaling in response to several 
endogenous agonists; dynamic cell spreading behavior; and a high density of #2b$3 to 
allow aggregation. 
Our studies began with a focus on the collagen receptor GPVI, where we 
discovered a novel mechanism of direct Src-family kinase activation by the GPVI 
proline-rich domain that accelerates GPVI signaling to allow for more efficient platelet 
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activation in response to collagen under whole blood flow.  The fact that this proline-rich 
region is highly conserved among all known GPVI receptors implies an importance for 
this domain in mediating collagen signaling in platelet biology.  This finding prompted us 
to investigate the response to collagen of thrombocytes, which do not contain a GPVI 
ortholog.  Our results, however, demonstrated that, even in the absence of GPVI, 
thrombocytes contain a receptor capable of robust collagen-induced activation and 
adhesion under flow.  Our focus shifted away from the collagen-GPVI axis and 
concentrated instead on the remarkable finding that chicken thrombocytes do not form 
aggregates under shear conditions.  Compared to any differences in the collagen receptor, 
the fact that thrombocytes contain a 10- to 20-fold lower density of #2b$3 on the cell 
surface could account for their profound difference in behavior under hemodynamic flow 
conditions.  To augment their aggregation response, platelets utilize positive feedback 
through an array of secondary agonists (ADP, thromboxane, and 5-HT), to which 
thrombocytes also lack a robust response.  Whether increased #2b$3 density, and 
therefore shear-resistant aggregation, preceded or co-evolved with the ability of platelets 
to maintain activation through secondary agonists is unknown. 
 The use of thrombocyte studies in zebrafish models has grown in popularity, 
based on the ease of genetic manipulation and relatively high-throughput whole organism 
hemostasis and thrombosis assays
144,160
.  Based on our findings, we would caution against 
the assumption that thrombocyte function in primitive vertebrates is completely 
analogous to platelet function in mammals.  The evolution of platelet responses to 
collagen under hemodynamic flow is most profoundly characterized by the response of 
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platelets after collagen-induced activation—aggregation and potentiation through 
secondary agonists.  GPVI, which appears in evolution after the emergence of true 
platelets in primitive mammals, may represent the evolutionary fine-tuning of the robust 
collagen signaling that is inherent in all hemostatic cells.  This fine-tuning may have been 
advantageous or even essential for mammalian survival following acute trauma, yet 
predisposes humans with atherosclerotic lesions to coronary and cerebrovascular 
occlusion. 
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Materials and methods 
Isolation of platelets from echidna and opossum 
Juvenile echidna and striped opossum studies were performed under supervision from the 
veterinarian staff at the Philadelphia Zoo.  A juvenile echidna and striped opossum were 
anesthetized using isofluorine inhalation.  Blood samples were collected from intra-nasal 
capillary beds into a syringe containing 15 U/mL heparin.  Platelet-rich plasma was 
obtained by centrifugation of whole blood following dilution into 1:2 blood:Tyrode’s 
buffer, as indicated in Chapter 2.  All platelet function studies were performed as 
described in Chapter 2.   
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Figure 4-1.  The response of echidna and opossum platelets to GPVI ligands.   
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Figure 4-1 (cont’d).  The response of echidna and opossum platelets to GPVI 
ligands.   
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Figure 4-1.  The response of echidna and opossum platelets to GPVI ligands.   
A. Platelets from echidna, opossum, or mouse blood were allowed to spread on glass 
slides coated with fibrinogen, CRP, or convulxin.  Platelets were fixed, permeabilized, 
and stained with Alexa-Fluor 594-conjugated phalloidin to detect actin filaments.   
B. Stimulation of echidna, opossum, or mouse platelets with GPVI agonists.  Platelets 
were stimulated with ADP, CRP, or convulxin for 10 min, and platelet activation was 
measured by the degree of fibrinogen binding, detected by flow cytometry.  For echidna 
platelets, a subset of platelets could be detected (gate 2) that bound fibrinogen in response 
to CRP stimulation.   
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Figure 4-2.  Alignment of GPVI sequences from opossum, mouse, and human.   
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Figure 4-2.  Alignment of GPVI sequences from opossum, mouse, and human.   
Amino acid residues implied in collagen or CRP binding are outlined in black, and 
conserved residues are shown in red text.  Residues of similar charge or non-conserved 
residues are shown in blue and orange text, respectively.  Polar residues believed to lie at 
the edge of the collagen-binding groove of GPVI are outlined in green.  Hydrophobic 
residues believed to form the floor of the GPVI collagen binding groove are outlined in 
brown.  Note the absence of many residues involved in collagen binding or formation of 
the collagen-binding groove in opossum GPVI.  Also, note the absence a 6-residue 
deletion in opossum GPVI compared to mouse or human GPVI that is believed to form 
the collagen-binding groove. 
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